EP3478417A1 - Dispositifs et méthodes d'extraction d'acides nucléiques - Google Patents

Dispositifs et méthodes d'extraction d'acides nucléiques

Info

Publication number
EP3478417A1
EP3478417A1 EP17821297.3A EP17821297A EP3478417A1 EP 3478417 A1 EP3478417 A1 EP 3478417A1 EP 17821297 A EP17821297 A EP 17821297A EP 3478417 A1 EP3478417 A1 EP 3478417A1
Authority
EP
European Patent Office
Prior art keywords
module
sample
volume
heater
input
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17821297.3A
Other languages
German (de)
English (en)
Other versions
EP3478417A4 (fr
Inventor
Victor Briones
Boris Andreyev
Adrienne C. LAM
Brian Ciopyk
Helen Huang
Keith Moravick
Colin Kelly
Jesus Ching
Jennifer ALBRECHT
Ryan CENA
Edward BIBA
Jonathan Hong
David D. Swenson
Adam De La Zerda
Gregory C. Loney
Valeria REVILLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visby Medical Inc
Original Assignee
Click Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Click Diagnostics Inc filed Critical Click Diagnostics Inc
Publication of EP3478417A1 publication Critical patent/EP3478417A1/fr
Publication of EP3478417A4 publication Critical patent/EP3478417A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502769—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/29—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using visual detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02—Adapting objects or devices to another
    • B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
    • B01L2200/027—Fluid interfacing between devices or objects, e.g. connectors, inlet details for microfluidic devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0645—Electrodes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0883—Serpentine channels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/18—Means for temperature control
    • B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
    • B01L2300/1822—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using Peltier elements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/18—Means for temperature control
    • B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
    • B01L2300/1827—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using resistive heater
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/06—Valves, specific forms thereof
    • B01L2400/0622—Valves, specific forms thereof distribution valves, valves having multiple inlets and/or outlets, e.g. metering valves, multi-way valves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/06—Valves, specific forms thereof
    • B01L2400/0633—Valves, specific forms thereof with moving parts
    • B01L2400/0644—Valves, specific forms thereof with moving parts rotary valves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • B01L7/525—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids

Definitions

  • the embodiments described herein relate to methods and devices for molecular diagnostic testing. More particularly, the embodiments described herein relate to disposable, self- contained devices and methods for molecular diagnostic testing. Particular embodiments described herein relate to disposable, self-contained devices and methods for purifying, reverse transcribing and detecting nucleic acids.
  • Known high throughput laboratory equipment generally processes many (96 to 384 and more) samples at a time, therefore central lab testing is done in batches.
  • Known methods for processing typically include processing all samples collected during a time period (e.g., a day) in one large run, with a turn-around time of hours to days after the sample is collected.
  • a time period e.g., a day
  • such known instrumentation and methods are designed to perform certain operations under the guidance of a skilled technician who adds reagents, oversees processing, and moves sample from step to step.
  • known laboratory tests and methods are very accurate, they often take considerable time, and are very expensive.
  • POC POC testing
  • Known POC testing options tend to be single analyte tests with low analytical quality. These tests are used alongside clinical algorithms to assist in diagnosis, but are frequently verified by higher quality, laboratory tests for the definitive diagnosis.
  • doctors and patients often determine a course of treatment before they know the diagnosis.
  • antibiotics are either not prescribed when needed, leading to infections; or antibiotics are prescribed when not needed, leading to new antibiotic-resistant strains in the community.
  • known systems and methods often result in diagnosis of severe viral infections, such as H1N1 swine flu, too late, limiting containment efforts. In addition, patients lose much time in unnecessary, repeated doctor visits.
  • a molecular diagnostic test device includes a housing, a reverse transcription module, an amplification module and a detection module.
  • the reverse transcriptase module is configured to receive an input sample and includes a heater such that the reverse transcription module can perform a reverse transcriptase polymerase chain reaction (RT-PCR) on the input sample.
  • the amplification module is configured to receive a cDNA sample from the reverse transcription module.
  • the amplification module includes a heater such that the amplification module can perform a polymerase chain reaction (PCR) on the input sample.
  • the detection module is configured to receive an output from the amplification module and a reagent formulated to produce a signal that indicates a presence of a target amplicon within the input sample.
  • the reverse transcription module, amplification module and the detection module are integrated within the housing such that the molecular diagnostic test device is a handheld device.
  • the signal is a non -fluorescent signal.
  • the signal is a visible signal characterized by a color associated with the presence of the target amplicon; and the detection module includes a detection surface from which the visible signal is produced, the detection surface visible via a detection opening defined by the housing.
  • the signal is a visible signal characterized by a color associated with the presence of the target amplicon, the reagent formulated such that the visible signal remains present for at least about 30 minutes.
  • the molecular diagnostic test device further comprises a power source disposed within the housing and configured to supply power to the amplification module, the power source including a DC battery having a nominal voltage of about 9V, the power source having a capacity of less than about 1200 mAh.
  • the molecular diagnostic test device further comprises a power source disposed within the housing; and a reagent module disposed within the housing, the reagent module including a sealed volume within which the reagent is contained, the reagent module including a reagent actuator configured to convey the reagent into a holding chamber fluidically coupled to the detection module when the reagent actuator is moved from a first position to a second position, the power source being electrically isolated from the amplification module when the reagent actuator is in the first position, the power source being electrically coupled to at least one of a processor or the amplification module when the reagent actuator is in the second position.
  • the molecular diagnostic test device further comprises a sample input module disposed within the housing, the sample input module including an inlet port, an outlet port, the inlet port configured to receive the input sample; and a sample actuator configured to convey the input sample via the outlet port and through a filter assembly when the sample actuator is moved from a first position to a second position, the sample actuator configured to remain locked in the second position.
  • the sample actuator is in a fixed position relative to at least one of the amplification module or the detection module when the sample actuator is in the second position.
  • the sample actuator is a non-electronic actuator configured to move irreversibly from the first position to the second position.
  • the molecular diagnostic test device is configured for one and only one use and is disposable.
  • an apparatus comprises a housing defining a detection opening; a reverse transcription module disposed within the housing, the reverse transcription module including a flow member and a heater, the flow member defining an reverse transcription flow path having an inlet portion configured to receive a sample, the heater fixedly coupled to the flow member such that the heater and the amplification flow path intersect at multiple locations; an amplification module disposed within the housing, the amplification module including a flow member and a heater, the flow member defining an amplification flow path having an inlet portion configured to receive a sample, the heater fixedly coupled to the flow member such that the heater and the amplification flow path intersect at multiple locations; a reagent module disposed within the housing, the reagent module containing a substrate formulated to catalyze the production of a signal by a signal molecule associated with a target amplicon; and a detection module defining a detection channel in fluid communication with an outlet portion of the amplification flow path and the reagent module, the detection module including a detection
  • the amplification and/or reverse transcription flow path is a serpentine flow path
  • the heater is a linear heater irreversibly coupled to the flow member.
  • the amplification and/or reverse transcription flow path is a serpentine flow path;
  • the heater is a heater assembly including a first linear heater coupled to a first end portion of the flow member, a second linear heater coupled to a second end portion of the flow member, a third linear heater coupled to a central portion of the flow member, the heater assembly coupled to of a first side the flow member via an adhesive bond.
  • the apparatus further comprises a power source disposed within the housing and configured to supply power to the heater, the power source having a nominal voltage of about 9VDC and a capacity of less than about 1200 mAh.
  • the apparatus further comprises a power module removably coupled to the housing, the power module including a power source having a nominal voltage of about 9VDC and a capacity of less than about 1200 mAh, the power module including an electronic circuit electrically coupled to the heater when the power module is coupled to the housing.
  • the apparatus further comprises a power source having a nominal voltage of about 9VDC and a capacity of less than about 1200 mAh; and an isolation member removably coupled to the housing, the power source being electrically isolated from the heater when the isolation member is coupled to the housing, the power source being electrically coupled to the heater when the isolation member is removed from the housing,
  • the reagent module including a reagent actuator configured to release the substrate into a holding chamber when the reagent actuator is moved from a first position to a second position, the movement of the isolation member being limited when the reagent actuator is in the first position.
  • the apparatus further comprises a power source disposed within the housing, the reagent module including a reagent actuator configured to release the substrate into a holding chamber when the reagent actuator is moved from a first position to a second position, the power source being electrically isolated from the heater when the reagent actuator is in the first position, the power source being electrically coupled to the heater when the reagent actuator is in the second position.
  • the apparatus further comprises a controller disposed within the housing, the controller implemented in at least one of a memory or a processor, the controller including a thermal control module configured to produce a thermal control signal to adjust an output of the heater.
  • the signal is a visible signal characterized by a color associated with the presence of the target amplicon; and the detection channel has a width of at least about 4mm.
  • the housing includes a mask portion configured to surround at least a portion of the detection opening, the mask portion configured to enhance visibility of the detection surface through the detection opening.
  • the reagent module includes a reagent formulated to produce the signal; and the signal is a non-fluorescent visible signal characterized by a color associated with the presence of the target amplicon, the reagent formulated such that the visible signal remains present for at least about 30 minutes.
  • an apparatus comprises a housing; a sample preparation module disposed within the housing and configured to receive an input sample, the sample preparation module including a filter assembly; a reverse transcription module disposed within the housing and configured to receive an output from the sample preparation module, the reverse transcription module including a flow member and a heater, the flow member defining an reverse transcription flow path having an inlet portion configured to receive a sample, the heater fixedly coupled to the flow member such that the heater and the amplification flow path intersect at multiple locations; an amplification module disposed within the housing and configured to receive an output from the reverse transcription module, the amplification module including a flow member and a heater, the flow member defining a serpentine flow path, the heater coupled to the flow member, the amplification module configured perform a polymerase chain reaction (PCR) on the output from the sample preparation module; and a detection module disposed within the housing and configured to receive an output from the amplification module, wherein the apparatus is configured for onetime use.
  • PCR polymerase chain reaction
  • the detection module is configured to receive a reagent formulated to produce a colorimetric signal that indicates a presence of a target organism in the input sample.
  • the apparatus further comprises a sample actuator configured to produce a force to convey the input sample through the filter assembly when the sample actuator is moved from a first position to a second position, the sample actuator configured to remain locked in the second position, the sample actuator including a locking shoulder configured to matingly engage a portion of the housing to maintain the sample actuator in the second position.
  • the sample preparation module is fixedly coupled within the housing.
  • the detection module is fixedly coupled within the housing and includes a detection surface from which a colorimetric signal that indicates a presence of a target organism in the input sample is produced, the detection surface visible via a detection opening defined by the housing.
  • the apparatus further comprises a fluid transfer module disposed within the housing, the fluid transfer module defining an internal volume within which the output of the sample preparation module flows when the fluid transfer module is actuated, the fluid transfer module configured to convey the output of the sample preparation module from the internal volume to the amplification module, the fluid transfer module being fixedly and fluidically coupled to the sample preparation module.
  • the fluid transfer module includes a plunger movably disposed within the internal volume such that movement of the plunger conveys the output of the sample preparation module from the internal volume to the amplification module.
  • the apparatus further comprises a power source disposed within the housing and configured to supply power to the amplification module, the power source having a capacity of less than about 1200 mAh.
  • the sample preparation module includes a wash container containing a gas wash and a liquid wash, the sample preparation assembly configured to convey the gas wash and the liquid wash through the filter assembly in series, further comprising: a wash actuator configured to produce a force to convey the gas wash through the filter assembly at a first time and the liquid wash through the filter assembly at a second time after the first time when the wash actuator is moved from a first position to a second position.
  • the heating element can heat a liquid in the mixing chamber to a temperature between 20C and lOOC. In some cases, the heating element can heat a liquid in the mixing chamber to a temperature between 20C and 50C. In some cases, the heating element can heat a liquid in the mixing chamber to a temperature between 85C and 95C. In some cases, the heating element can hold a liquid in the mixing chamber at a constant temperature between 20C and 50C. In some cases, the heating element can hold a liquid in the mixing chamber at a constant temperature between 85C and 95C. In some cases, the heating element can hold a liquid in the mixing chamber at a constant temperature for a time between 0.1 to 24 hours.
  • the heating element can hold a liquid in the mixing chamber at a constant temperature for a time between 0.1 to 1 hour. In some cases, the heating element can hold a liquid in the mixing chamber at a constant temperature for a time between 1 second and 30 minutes. In some cases, the heating element can hold a liquid in the mixing chamber at a constant temperature for a time between 1 second and 10 minutes.
  • the reverse transcription chamber of step (b) further comprises a mixing chamber and a serpentine channel.
  • the mixing chamber can hold a volume between lOul and lOml.s In some cases, the mixing chamber can hold a volume between lOul and lml. In some cases, the mixing chamber can hold a volume of 300ul.
  • the serpentine channel is designed to have a cross-section with an aspect ratio (channel height to width) to maximize the area in contact with heater allowing efficient heat coupling to the fluid.
  • the device is designed to perform and analyze multiplexed PCRs.
  • the reverse transcription module further comprises a lyophilized pellet comprising reverse transcriptase enzyme and reagents.
  • the reverse transcription module contains a reagent chamber containing reverse transcriptase enzyme and reagents required for a reverse transcriptase polymerase chain reaction.
  • the reverse transcriptase enzyme and reagents are present as a lyophilized pellet.
  • the reverse transcriptase enzyme and reagents are present with the DNA polymerase enzyme and PCR reagents.
  • a method for DNA preparation comprises obtaining a biological sample comprising one or more biological entities comprising RNA; capturing said one or more biological entities on a filter; eluting said one or more biological entities from said filter; and lysing said one or more biological entities, incubating the lysed biological entities with a reverse transcriptase enzyme and sufficient reagents to perform a reverse transcription reaction, thereby preparing a plurality of DNA molecules therefrom, wherein said method prepares said DNA molecules from said one or more biological entities within 10 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the method further comprises that the filter consists of two filter membranes, a first filter membrane and a second filter membrane with a smaller pore size than the first filter membrane.
  • the method further comprises a wash step, whereby once the biological entities are captured on the filter the filter and biological entities are washed with an air wash.
  • a method for DNA preparation comprises obtaining a biological sample comprising one or more biological entities, wherein the biological entities comprise RNA; lysing said one or more biological entities, thereby releasing a plurality of RNA molecules therefrom; and performing a reverse transcriptase reaction on the released RNA molecules to produce a plurality of DNA molecules, wherein said method extracts said nucleic acid molecules from said one or more biological entities within 5 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the method is performed by a handheld device.
  • a quality sufficient to successfully perform a polymerase chain reaction comprises nucleic acid molecules which amplify with at least 70% efficiency as determined by a qPCR standard curve.
  • the method produces at least 100 ⁇ _, of a solution containing the nucleic acid molecules. In some cases, the method produces at least 300 ⁇ _, of a solution containing the nucleic acid molecules. In some cases, the method produces at least 500 ⁇ , of a solution containing the nucleic acid molecules. In some cases, the method further comprises catching biological entities on a filter and subjecting the biological entities and filter to an air wash. In some cases, the biological entities are washed with a volume of air sufficient to dry the filter. In some cases, the biological entities are washed with at least about 1.5 mL of air.
  • a device configured to perform a method as described herein, wherein said device comprises an input port, configured to receive said biological sample comprising one or more biological entities; a holding tank, operably coupled to said input port, an inactivation section, and containing a heating element; and an output port.
  • the device further comprises a permanent vent.
  • the holding tank further comprises an electrical probe which can sense the presence of liquid in the holding tank.
  • the inactivation chamber comprises a serpentine path.
  • a method of DNA preparation comprises conveying a biological sample comprising RNA into a sample input module of a molecular diagnostic test device; and actuating the molecular diagnostic test device to: lyse the biological sample in a lysing module, convey the biological sample from the lysing module to a reverse transcription module, the reverse transcription module including a heater and defining a first reaction volume and a second reaction volume, and further comprising lyophilized reagents for a reverse transcription reaction; maintain an input solution containing the biological sample and the reagents for reverse transcription within the first reaction module to reverse transcribe at least a portion of the biological sample thereby producing a plurality of DNA molecules; activate the heater to heat a portion of the lysing module to produce an inactivation temperature zone within the second reaction volume; and produce a flow of the input solution within the second reaction volume such that a volume of the input solution is heated within the inactivation temperature zone to inactivate an enzyme within the input solution.
  • the volume of the input solution is at least 10 microliters. In some cases, the volume of the input solution is produced within five minutes or less.
  • the second reaction volume is a serpentine flow path. In some cases, a wall of the lysing module that defines the second reaction volume has a surface area, a ratio of the surface area to the second reaction volume being greater than about 10 cm-1.
  • the volume of the input solution is heated to an inactivation temperature of between about 57 degrees Celsius and about 100 degrees Celsius for a time period from about 15 seconds. In some cases, the flow of the input solution is such that the volume of the input solution is heated to an inactivation temperature of between about 92 degrees Celsius and about 98 degrees Celsius for a time period of at least about 25 seconds.
  • the first reaction volume is in fluid communication with the second reaction volume; and the reverse transcription module defines a vent opening into the first reaction volume.
  • the volume of the input solution is heated to an inactivation temperature of at least about 95 degrees Celsius; and the input solution within the first reaction module contains at least one of a salt or a sugar formulated to raise a boiling temperature of the input solution.
  • the portion of the reverse transcription module is a second portion
  • the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: heat a first portion of the lysing module to produce a lysing temperature zone within the second reaction volume, the flow of the input solution within the second reaction volume being such that the volume of the input solution is heated within the lysing temperature zone to lyse a biological entity within the volume of the input solution.
  • the actuating the molecular diagnostic test device causes the molecular diagnostic test device to: convey the biological sample from the sample input module through a filter to retain a biological entity with the biological sample on the filter; and produce a flow of an elution buffer through the filter to produce the input solution and convey the input solution to the lysing module.
  • the actuating the molecular diagnostic test device includes moving a sample actuator to produce a pressure within the sample input module to convey the biological sample from the sample input module towards the lysing module.
  • the sample actuator is a non-electronic actuator.
  • the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: receive an electronic signal from a sensor within the reverse transcription module, the electronic signal indicating the presence of the input solution within the first reaction module; and activate the heater in response to the electronic signal.
  • the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: heat a portion of an amplification module within the molecular diagnostic test device to amplify a nucleic acid from the plurality of nucleic acid molecules to produce an output containing a target amplicon; and convey the output to a detection module of the molecular diagnostic test device.
  • the method further comprises viewing a visible signal indicating a presence of the target amplicon; and discarding, after the viewing, the molecular diagnostic test device.
  • an apparatus comprises a housing; a sample input module defining an input reservoir configured to receive a biological sample, the biological sample containing a biological entity; a lysing module disposed within the housing, the lysing module including a heater and first flow member, the first flow member defining a first volume and a second volume, the first volume configured to receive an input solution containing at least the biological sample and a lysis buffer, the heater coupled to the first flow member and configured to convey thermal energy into the second volume to A) lyse at least a portion of the biological sample thereby releasing a plurality of nucleic acid molecules and B) inactivate an enzyme within the input solution when a volume of the input solution flows through the second volume; a reverse transcription module disposed within the housing, the reverse transcription module including a heater and first flow member, the first flow member defining a first volume and a second volume, the first volume configured to receive an input solution containing at least the biological sample and a lysis buffer, the first volume further containing ly
  • the second volume of the reverse transcription module is a serpentine flow path.
  • a wall of the reverse transcription module that defines the second volume has a surface area, a ratio of the surface area to the second reaction volume being greater than about 10 cm-1.
  • the first volume is in fluid communication with the second reaction volume; and the reverse transcription module defines a vent opening into the first volume.
  • the lysing module includes a sensor disposed within the first volume, the sensor configured to produce an electronic signal indicating the presence of the input solution within the first module, the heater activated in response to the electronic signal.
  • the heater is a first heater; the second flow member defines an amplification flow path; and the amplification module includes a second heater different from the first heater, the second heater coupled to the second flow member and configured to convey thermal energy into the amplification flow path to amplify the nucleic acid molecule from the plurality of nucleic acid molecules.
  • the apparatus further comprises a non-electronic sample actuator to produce a pressure within the sample input module to convey the biological sample from the sample input module towards the lysing module; and a fluid pump disposed within the housing, the fluid pump configured to produce a flow of the input solution from the lysing module to the amplification module.
  • the flow of the input solution from the lysing module to the amplification module is in a first direction; and the lysing module includes a check valve to configured to prevent a flow of the input solution in a second direction.
  • a device comprising a holding tank which contains two electrical probes which may be used to determine the electrical resistance of the fluid within the holding tank, thus determining whether liquid has entered the holding tank.
  • an apparatus comprises a reverse transcription module disposed within a molecular diagnostic test device, the reverse transcription module including a heater and a flow member, the flow member defining a first volume and a second volume, the first volume containing a lyophilized reverse transcriptase enzyme and configured to receive an input solution containing at least a biological sample, the heater coupled to the flow member and configured to convey thermal energy into the reverse transcription module to facilitate a thermal reaction on the input solution when a volume of the input solution flows through the second volume; and a sensor at least partially disposed within the first volume the sensor configured to produce a signal when the input solution is within the first volume, a portion of the molecular diagnostic test device being actuated in response to the signal.
  • the senor includes a first electrode and a second electrode, the first electrode disposed within the first volume, the second electrode disposed within the second volume, spaced apart from the first electrode, the sensor configured to determine an electrical resistance of the input solution between the first electrode and the second electrode and produce the signal associated with the electrical resistance.
  • the heater is actuated in response to the signal.
  • the apparatus further comprises an amplification module disposed within the housing, the amplification module including an amplification flow member configured to receive the volume of the input solution from the reverse transcription module, the amplification module configured to amplify a nucleic acid molecule from a plurality of nucleic acid molecules within the volume of the input solution to produce an output containing a target amplicon, the amplification module being actuated in response to the signal.
  • the amplification module disposed within the housing, the amplification module including an amplification flow member configured to receive the volume of the input solution from the reverse transcription module, the amplification module configured to amplify a nucleic acid molecule from a plurality of nucleic acid molecules within the volume of the input solution to produce an output containing a target amplicon, the amplification module being actuated in response to the signal.
  • a method for increasing the concentration of a biological entity in a liquid comprises obtaining a plurality of hydrogel particles functionalized with affinity baits for said biological entity; incubating a first volume of the liquid containing the biological entity with the hydrogel particles; flowing the liquid containing the biological entity and the hydrogel particles through a filter with a pore size such that the hydrogel particles cannot pass through the filter; and eluting the hydrogel particles and bound biological entity from the filter in a second volume of liquid, wherein the second volume of liquid is smaller than the first volume of liquid, thus increasing the concentration of the biological entity in the liquid.
  • FIG. 1 depicts data generated from a real-time PCR reaction performed on DNA extracted from clinical samples utilizing the methods provided herein.
  • FIG. 2 depicts data generated from a real-time PCR reaction performed on DNA extracted from clinical samples utilizing standard DNA extraction methods.
  • FIG. 3 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 1 17) utilizing the methods provided herein versus standard DNA extraction methods.
  • FIG. 4 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 1 17) utilizing the methods provided herein versus standard DNA extraction methods.
  • FIG. 5 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122), a clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods.
  • FIG. 6 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods.
  • FIG. 7 depicts a comparison of data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA utilizing different sets of primers.
  • FIG. 8 depicts a comparison of data generated from a real-time PCR reaction performed on C. trachomatis DNA utilizing different sets of primers.
  • FIG. 9 depicts data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA spiked into a sample and PCR mixture to test for sample inhibition.
  • FIG. 10 is a schematic illustration of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
  • FIG. 11 is an exploded view of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
  • FIG. 12 depicts an example of a sample preparation device amenable to performing the methods as described herein.
  • FIG. 13 is a perspective view of a lysing module according to an embodiment, which is amenable to performing the methods as described herein.
  • FIG. 14 is an exploded view of the lysing module shown in FIG. 13.
  • FIG. 15 is a top view of a portion of the lysing module shown in FIG. 13.
  • FIG. 16 is a cross-sectional view of the lysing module shown in FIG. 13.
  • FIGS. 17 and 18 is are perspective views of a lysing module according to an embodiment, which can perform any of the methods described herein.
  • FIG. 19 is a bottom view of the lysing module shown in FIGS. 17 and 18.
  • FIG. 20 is a cross-sectional view of the lysing module shown in FIGS. 17 and 18 taken along line Xi-Xi in FIG. 19.
  • FIG. 21 is a cross-sectional view of the lysing module shown in FIGS. 17 and 18 taken along line X 2 -X 2 in FIG. 19.
  • FIG. 22 is a perspective view of a portion of the lysing module shown in FIGS. 17 and 18.
  • FIG. 23 is a schematic illustration of a portion of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
  • FIG. 24 is a schematic illustration of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
  • FIG. 25 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure.
  • FIG. 26 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure.
  • FIG. 27 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure.
  • FIG. 28 illustrates a block diagram of a device including a reverse transcription module.
  • FIG. 29 illustrates a temperature profile in a reverse transcription module.
  • FIG. 30 illustrates a possible chamber design for a reverse transcription module.
  • FIG. 31 illustrates the bottom view of a possible chamber design for a reverse transcription module.
  • FIG. 32 illustrates an example of a functionalized nanoparticle.
  • FIG. 33 illustrates a proposed model of functionalized nanoparticle binding to viruses.
  • FIG. 34 illustrates a block diagram of a device including a reverse transcription module.
  • FIG. 35 is a schematic illustration of a portion of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
  • FIG. 36 illustrates capture of viral nucleic acid with affinity particles
  • FIG. 37 illustrates capture of infectious viral particles with affinity particles.
  • the devices and methods are utilized for the extraction of nucleic acid molecules from a biological sample. In some cases, the devices and methods are utilized for the purification of nucleic acid molecules from a biological sample. In some cases, the devices and methods are utilized to produce and detect a cDNA from an RNA isolated from a biological sample.
  • the devices described herein may include self-contained, handheld devices. The devices described herein may include one or more components that aid in the extraction, purification, and/or processing of a biological sample and the nucleic acids contained therein.
  • the methods include the use of a device that includes one or more components that aid in the extraction, purification, and/or processing of a biological sample and the nucleic acids contained therein.
  • the processing of a biological sample may include a reverse transcription step which may be achieved by a reverse transcriptase.
  • a method for nucleic acid extraction may include one or more steps including: (a) obtaining a biological sample comprising one or more biological entities; (b) capturing the one or more biological entities on a filter; (b) washing the filter with a wash solution and/or air; (c) eluting the one or more biological entities from the filter; and (d) lysing the one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom.
  • the wash solution comprises bovine serum albumin and/or a detergent.
  • the wash solution comprises about 0.1% to 5% bovine serum albumin.
  • the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%), or 5%) bovine serum albumin.
  • the wash solution comprises about 0.1% to 20% detergent.
  • the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%), or 10%) detergent.
  • the detergent is Tween-20.
  • the method may not require use of a filter. In other embodiments the method may use a filter but not require a wash solution.
  • the method further includes a step of reverse transcribing an RNA molecule to produce a cDNA molecule.
  • the method includes a preliminary step for increasing the concentration of one or more biological entities in the sample.
  • This step may involve the use of affinity beads designed to bind to pathogens or analytes in the sample.
  • the affinity beads may be nanoparticles or microparticles, (functionalized nanoparticles or functionalized microparticles ).
  • the method involves obtaining or providing a biological sample.
  • the biological sample can be derived from a non-cellular entity comprising polynucleotides (e.g., a virus) or from a cell -based organism (e.g., member of archaea, bacteria, or eukarya domains).
  • the biological sample will contain one or more biological entities that comprise one or more polynucleotides or nucleic acid molecules.
  • a "nucleic acid molecule”, “nucleic acid” or “polynucleotide” may be used interchangeably throughout and may refer to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) including known analogs or a combination thereof unless otherwise indicated.
  • Nucleic acid molecules to be profiled herein can be obtained from any source of nucleic acid.
  • the nucleic acid molecule can be single-stranded or double-stranded. In some cases, the nucleic acid molecules are RNA.
  • RNA can include, but is not limited to, mRNAs, tRNAs, snRNAs, rRNAs, retroviruses, small non-coding RNAs, microRNAs, polysomal RNAs, pre-mRNAs, intronic RNA, viral RNA, cell free RNA and fragments thereof.
  • the non-coding RNA, or ncRNA can include snoRNAs, microRNAs, siRNAs, piRNAs and long nc RNAs.
  • the nucleic acid molecules are DNA.
  • the DNA can be mitochondrial DNA, complementary DNA (cDNA), or genomic DNA.
  • the nucleic acid molecules are genomic DNA (gDNA).
  • the DNA can be plasmid DNA, cosmid DNA, bacterial artificial chromosome (BAC), or yeast artificial chromosome (YAC).
  • the DNA can be derived from one or more chromosomes. For example, if the DNA is from a human, the DNA can derived from one or more of chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, X, or Y.
  • the source of nucleic acid for use in the methods and compositions described herein can be a sample comprising the nucleic acid.
  • the methods involve capturing one or more biological cells or biological entities (e.g., a virus) with a capture particle or affinity bead.
  • biological fluids e.g., blood, plasma, homogenized tissue, urine.
  • the capture methods may be generic and bind to any cells or biological entities in a sample, or may be specific to a class or type of biological entity.
  • the capture methods may be specific to a family of pathogens, for example a family of bacteria or viruses.
  • the capture methods may be specific to a single species of pathogen, for example a single species of bacteria or virus.
  • the capture methods may be designed to bind to several related or unrelated pathogens.
  • the capture methods may be designed to bind one or more of the following pathogens: Ebola virus, Sudan virus, Ta ' i Forest virus, Bundibugyo virus, Yersinia pestis, Zika virus, Plasmodium falciparum, Leptospira interrogans, Dengue virus, Chikungunya virus, Crimean-Congo hemorrhagic fever virus, and Lassa virus.
  • pathogens Ebola virus, Sudan virus, Ta ' i Forest virus, Bundibugyo virus, Yersinia pestis, Zika virus, Plasmodium falciparum, Leptospira interrogans, Dengue virus, Chikungunya virus, Crimean-Congo hemorrhagic fever virus, and Lassa virus.
  • the capturing and concentration of a biological entity is achieved by use of a particle which the biological entity adheres to.
  • the particle may be made of any substance.
  • the particle is a hydrogel particle.
  • the particle is a hydrogel particle based on cross-linked N-isopropylacrylamide (NIP Am).
  • NIP Am cross-linked N-isopropylacrylamide
  • the particle may comprise a core with a porous coating. An example of such a particle is shown in FIG. 33.
  • the particle may have a porous coating which performs a size exclusion function limiting the biological entities which may bind the particle.
  • the particle may be functionalized with a variety of affinity baits to facilitate the binding and retention of biological targets.
  • the functionalized particle may be composed of a core containing high affinity aromatic baits, surrounded by a sieving shell.
  • aromatic baits include: Cibacron Blue, Allylamine and Methacrylate.
  • the outer shell may be tailored for active exclusion of high abundance proteins.
  • the outer shell may contain vinyl sulfonic acid for active molecular sieving of high-abundance proteins.
  • the functionalized particles may be tailored to capture target analytes from a variety of complex biological matrices, including blood, serum, plasma, saliva and nasopharyngeal fluids.
  • the target analytes may be proteins, nucleic acids, viruses or bacteria.
  • the functionalized particles may capture live bacteria and intact viruses without causing damage.
  • the functionalized particles may be nanoparticles. In some cases the functionalized nanoparticles have an average diameter of about 10-100, 20-40, 30-50 or 20-30 nm. In some embodiments, a functionalized nanoparticle may have a diameter of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more than 50 nm In some embodiments, the functionalized particles may be microparticles. In some cases the functionalized microparticles have an average diameter of about 10-100, 20-40, 30-50 or 20-30 ⁇ .
  • a functionalized microparticle may be created by attaching one or more functionalized nanoparticles to a larger particle.
  • the larger particle may have a diameter of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more than 50 ⁇ . In some cases the larger particle may have a diameter between about 1 and 10, 1 and 5, 5 and 10, 3 and 8, or 2 and 7 ⁇ .
  • the larger particle may be a hydrogel particle or a different type of particle. In some cases, the larger particle is a polystyrene particle.
  • a larger particle may be bound to an average of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, or more than 50 functionalized nanoparticles .
  • the functionalized nanoparticles may be covalently bound to the larger particle.
  • the functionalized nanoparticle chemistry may incorporate amine containing monomers into the hydrogel matrix.
  • one or more functionalized nanoparticles or functionalized microparticles designed to bind said biological entity may be added to the sample.
  • the functionalized nanoparticles or functionalized microparticles are extracted from the sample.
  • the functionalized nanoparticles or functionalized microparticles are extracted by flowing the sample through a filter with a pore size smaller than the size of the particles.
  • the functionalized nanoparticles or functionalized microparticles and associated biological entities may subsequently be washed off the filter and nucleic acids may be released by lysis.
  • functionalized nanoparticles or functionalized microparticles are added to a sample prior to processing the sample through a method of device as described herein.
  • functionalized microparticles will be lyophilized and put into sample collection tubes, so upon collection of a sample into the tube, the functionalized microparticles will hydrate and actively capture the relevant biological entities.
  • the sample and functionalized microparticle mixture may be used directly in the methods and devices described herein.
  • the incubation step for the functionalized microparticles and the biological entities may be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes. In some cases the incubation step is between 1 and 60, 1 and 30, 1 and 20, 1 and
  • the incubation step is less than 1 minute. In some cases, the incubation step is performed at room temperature. In some cases, the incubation step is performed at a temperature between about 15 and 80, 20 and 40, 20 and 30, 20 and 25, or 25 and 30 °C.
  • the functionalized nanoparticles or functionalized microparticles may provide an enrichment of a biological entity in a solution by about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 , 13, 14, 15,
  • Using a method or device as described herein with a functionalized microparticle may result in an increase in the amount of nucleic acid extracted or prepared of about 2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 , 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more than 30 fold compared to the same method or device without the functionalized microparticle .
  • the methods involve capturing one or more biological cells or biological entities (e.g., a virus, or a functionalized microparticle with trapped virus particles) present in the biological sample on a filter membrane.
  • the filter membrane may be of any suitable material, non- limiting examples including nylon, cellulose, polyethersulfone (PES), polyvinylidene difluoride (PVDF), polycarbonate, borosilicate glass fiber and the like.
  • the filter membrane is nylon.
  • the filter membrane has an average pore size of about 0.2 ⁇ to about 20 ⁇ .
  • the filter membrane may have an average pore size of about 0.2 ⁇ , about 0.5 ⁇ , about 1 ⁇ , about 2 ⁇ , about 3 ⁇ , about 4 ⁇ , about 5 ⁇ , about 6 ⁇ , about 7 ⁇ , about 8 ⁇ , about 9 ⁇ , about 10 ⁇ , about 11 ⁇ , about 12 ⁇ , about 13 ⁇ , about 14 ⁇ , about 15 ⁇ , about 16 ⁇ , about 17 ⁇ , about 18 ⁇ , about 19 ⁇ , about 20 ⁇ , or greater than 20 ⁇ .
  • the surface of the filter membrane may be chemically treated or coated in such a way as to improve the binding of a biological cell or entity to the membrane.
  • the filter membrane may be treated with sodium polyphosphate.
  • Clinical swab samples may contain mucus (or other substances) which can lead to clogging of the filter used in sample prep. If the filter is clogged then pressures may build up which may lead to leaks in the fluidic path of the sample prep device and/or tears or breaks in the capture filter itself.
  • a second filter may be provided which sits next to a first filter.
  • a mesh screen may be placed on the input side of the 5 micron nylon filter. This may reduce pressure from mucus samples and also prevent the 5 micron nylon filter from breaking.
  • a mesh screen could also be placed on the exit side of the 5 micron nylon filter which would also prevent the 5 micron nylon filter from breaking, however this may not reduce the pressure required to push a sample (mucus) through.
  • the mesh screen may be made from any plastic materials and may contain pore sizes from 1 micron to 1000 microns.
  • the mesh screen may be a woven nylon mesh with 100 micron pores.
  • the mesh screen is assembled into the housing that also contains the 5 micron nylon filter.
  • the second filter may have a much larger pore size than the first filter and prevent clogging of the first filter.
  • the first filter may have a pore size of about 0.1-20, 1-15, 1-10, 5-10, 1-5 or 0.1-1 ⁇ while the second filter has a pore size of about 10-1000, 50-500, 100- 500, 50-100, or 100-200 ⁇ .
  • the first filter has a pore size of 5 ⁇ and the second filter has a pore size of 100 ⁇ .
  • the mesh filter may also be made from non-woven polypropylene.
  • the mesh screen may have a thickness of about 150 ⁇ , 200 ⁇ or greater than 200 ⁇ .
  • the wash step may be utilized to, for example, remove any undesired material from the membrane.
  • the wash step may involve pushing or forcing a fluid solution over or through the membrane (e.g., a buffer).
  • the volume of wash solution may be from about 10 ⁇ . to about 50 mL.
  • the volume of wash solution may be about 10 ⁇ ., about 50 ⁇ ., about 100 ⁇ ., about 200 ⁇ ., about 300 ⁇ ., about 400 ⁇ , about 500 ⁇ ., about 600 ⁇ ., about 700 ⁇ ., about 800 ⁇ ., about 900 ⁇ ., about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL or greater than 50 mL.
  • the wash step may involve pushing or forcing air over or through the membrane. This step may be advantageous in decreasing the volume of sample buffer that is carried over into the lysis buffer.
  • the volume of air wash may be from about 0.1 ⁇ L to about 100L, or aboutlO ⁇ L to about 50 mL.
  • the volume of air wash may be about 10 ⁇ ., about 50 ⁇ ., about 100 ⁇ ., about 200 ⁇ ., about 300 ⁇ ., about 400 ⁇ L, about 500 ⁇ ., about 600 ⁇ about 700 ⁇ ., about 800 ⁇ ., about 900 ⁇ L, about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL or greater than 50 mL.
  • an air wash volume of about 1 -5 mL may be preferred, For example an air wash may be have a volume of about 1.5mL. In cases where an air wash is used the subsequent liquid wash may be more effective and/or the final eluted sample may be cleaner than if no air wash were used.
  • the wash step involves both a fluid wash step and an air wash step, performed in any order.
  • the wash solution comprises bovine serum albumin and/or a detergent.
  • the wash solution comprises about 0.1% to 5% bovine serum albumin.
  • the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin.
  • the wash solution comprises about 0.1% to 20% detergent. In some cases, the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20. In some embodiments, the bovine serum albumin and/or detergent increase the viscosity of the wash solution in manner which increases the surface area of the filter contacted with the wash solution during a wash step as compared to a wash solution lacking one or both of bovine serum albumin and detergent.
  • the biological cells or entities captured on the membrane may be lysed or otherwise disrupted so as to release a plurality of nucleic acid molecules contained therein.
  • the methods and devices of this disclosure may use chemical, enzymatic and/or thermal methods to lyse the sample. In some embodiments the methods and devices of this disclosure do not use ultrasound to lyse the sample.
  • the cells may be lysed by heating the sample. For example the sample may be heated to greater than about 90°C for longer than about 10 seconds. In some examples heating the sample to about 95°C for about 20 seconds is seen to be sufficient to lyse the sample.
  • lysis involves flowing a lysis buffer over the biological cells or entities captured on the membrane.
  • the lysis buffer is flowed through the filter membrane.
  • the lysis buffer is back-flowed through the filter membrane.
  • the lysis buffer may be osmotically imbalanced so as to force fluid into the cells to rupture the cell membranes.
  • the lysis buffer may include one or more surfactants or detergents.
  • Non-limiting examples of surfactants or detergents that may be used include: nonionic surfactants including polyoxyethylene glycol alkyl ethers (sold as Brij® series detergents including Brij® 58, Brij® 52, Brij® L4 and Brij® L23), octaethylene glycol monododecyl ether, pentaethylene glycol monododecyl ether, polyoxypropylene glycol alkyl ethers, glucoside alkyl ethers (e.g., decyl glucoside, lauryl glucoside, octyl glucoside), polyoxyethylene glycol octylphenol ethers (e.g., Triton X-100), polyoxyethylene glycol alkylphenol ethers (e.g., nonoxynol-9), glycerol alkyl esters (e.g., glyceryl laurate), polyoxyethylene glycol sorbitan alkyl esters
  • dodecyldimethylamine oxide poloxamers including those sold under the Pluronic®, Synperonic® and Kolliphor® tradenames, and polyethoxylated tallow amine (POEA); anionic surfactants including ammonium lauryl sulfate, ammonium perfluorononanoate, docusate,
  • perfluorooctanoic acid potassium lauryl sulfate, sodium alkyl sulfate, sodium dodecyl sulfate, sodium dodecylbenzenesulfonate, sodium laurate, sodium lauryl ether sulfate, sodium lauroyl sarcosinate, sodium myreth sulfate, sodium pareth sulfate, sodium stearate; cationic surfactants including benzalkonium chloride, benzethonium chloride, bronidox, cetrimonium bromide, cetrimonium chloride, distearyldimethylammonium chloride, lauryl methyl gluceth-10
  • hydroxypropyl dimonium chloride octenidine dihydrochloride, olaflur, and tetram ethyl ammonium hydroxide
  • Zwitterionic surfactants including CHAPS detergent, cocamidopropyl betaine, cocamidopropyl hydroxysultaine, dipalmitoylphosphatidylcholine, lecithin, hydroxysultaine, and sodium lauroamphoacetate.
  • the lysis buffer may contain an antifoaming agent for preventing or minimizing foaming.
  • antifoaming agents include Antifoam SE-15, Antifoam 204, Antifoam Y-30.
  • the lysis buffer may contain a preservative, for example an antimicrobial agent.
  • antimicrobials may include ProClinTM 150, ProClinTM 200, ProClinTM 300, and ProClinTM 950.
  • the lysis buffer may include one or more agents that prevent degradation of the RNA, such as, for example, an RNAse inhibitor.
  • the volume of lysis buffer flowed over the membrane can be from about 10 ⁇ ⁇ to about 50 mL.
  • the volume of lysis buffer may be about 10 ⁇ ⁇ , about 50 ⁇ ⁇ , about 100 ⁇ ., about 200 ⁇ , about 300 ⁇ ⁇ , about 400 ⁇ ⁇ , about 500 ⁇ ⁇ , about 600 ⁇ ⁇ , about 700 ⁇ ., about 800 ⁇ ., about 900 ⁇ ., about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL or greater than 50 mL.
  • the lysis buffer contains one or more enzymes.
  • the one or more enzymes comprise Proteinase K.
  • Proteinase K may be present in the lysis buffer at a concentration of about 0.001 mg/mL to about 10 mg/mL.
  • the concentration of proteinase K in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL.
  • the one or more enzymes comprise lysozyme to process gram-positive organisms.
  • Lysozyme may be present in the lysis buffer at a concentration of about 0.001 mg/mL to about 10 mg/mL.
  • the concentration of lysozyme in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL.
  • the one or more enzymes comprise zymolyase to process yeast. Zymolase may be present in the lysis buffer at a concentration of about 0.001 mg/
  • concentration of zymolase in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL.
  • Additional enzymes include, without limitation, lyticase, chitinase or gluculase, for e.g., the extraction of nucleic acids from yeast.
  • the enzymes may be added in sequence. For example, lysozyme may be added first, followed by an incubation period, and subsequently followed by addition of proteinase K and an additional incubation period.
  • the lysis buffer does not contain any enzymes.
  • the methods may involve one or more incubation steps.
  • the one or more incubation steps may be performed in the lysis buffer in order to ensure complete lysis or disruption of the biological cell or entity and/or to destroy any inhibitory protein that may be present.
  • the incubation step may involve holding the biological cell or entity in the lysis buffer for a period of time.
  • the incubation step involves holding the biological cell or entity in the lysis buffer for a period of time at a specified temperature.
  • the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds to about 48 hours.
  • the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours.
  • the biological cell or entity is incubated in the lysis buffer at a specified temperature, for example, from about 4° C to about 75° C.
  • a specified temperature for example, from about 4° C to about 75° C.
  • the biological cell or entity is incubated in the lysis buffer at a temperature of about 4° C, about 10° C, about 15° C, about 20° C, about 25° C, about 30° C, about 40° C, about 45° C, about 50° C, about 55° C, about 60° C, about 65° C, about 70° C, about 75° C or greater than 75° C.
  • the temperature conditions will be selected so as to promote disruption of the biological cell or entity.
  • the temperature may be selected such that the enzyme retains catalytic activity.
  • the temperature may be selected for optimal catalytic activity of the lysis enzyme.
  • the temperature may also be selected to neutralize any inhibitory proteins within the sample, but should not destroy or disrupt the integrity of the nucleic acid molecules released therefrom.
  • the lysis buffer does not contain any enzymes.
  • an additional incubation step may be performed to, for example, destroy or inactivate the one or more interfering components (e.g., Proteinase K) used in the lysis step.
  • the subsequent incubation step may be from about 0.01 seconds to about 48 hours.
  • the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours.
  • the additional incubation step may occur at a temperature between about 57° C and about 100° C.
  • the additional incubation step may occur at a temperature of about 57° C, about 58° C, about 59° C, about 60° C, about 61° C, about 62° C, about 63° C, about 64° C, about 65° C, about 66° C, about 67° C, about 68° C, about 69° C, about 70° C, about 71° C, about 72° C, about 73° C, about 74° C, about 75° C, about 76° C, about 77° C, about 78° C, about 79° C, about 80° C, about 81° C, about 82° C, about 83° C, about 84° C, about 85° C, about 86° C, about 87° C, about 88° C, about 89° C, about 90° C, about 91° C, about 92° C, about 93° C, about 94° C , about 95° C, about 96° C, about 97° C, about 97°
  • the extracted nucleic acids may be utilized at this stage for any downstream processes, without any purification steps.
  • the extracted nucleic acid molecules may be used in one or more amplification reactions.
  • the extracted nucleic acid molecules may be used in one or more polymerase chain reactions (PCR). Any known method of PCR may be performed using the extracted nucleic acid molecules provided herein.
  • the RNA when RNA is extracted, the RNA may be reverse transcribed (i.e., using a reverse transcriptase) prior to performing the downstream application. Briefly this may occur as in the diagram in FIG. 28, the sample is processed in a pre-sample prep stage which may include concentration, purification and lysis of the sample, the sample then moves to a RT-PCR step in which RNA molecules are reverse transcribed to DNA molecules, these move to a mixing compartment and thence to a PCR module and a detection module. Optionally this may occur as in FIG. 34 which includes an additional step between the pre-sample prep stage and the RT-PCR step in which the sample is mixed with reagents for performing the reverse transcriptase reaction.
  • the steps of reverse transcription and PCR may occur in the same module, in this case the amplification module.
  • Extracted RNA molecules may be incubated with one or more reverse transcriptase enzymes at a suitable temperature for reverse transcription to occur.
  • the reverse transcriptase enzyme may be provided alone or with a buffer suitable for the reverse transcriptase reaction.
  • the reverse transcriptase may be provided with a concentrated buffer designed to adjust the conditions of the extracted nucleic acid solution. In other cases no additional components are provided and the lysis buffer is suitable for reverse transcriptase.
  • the incubation step may involve holding the biological cell or entity in the buffer for a period of time. In some cases, the incubation step involves holding the RNA molecule in the buffer for a period of time at a specified temperature.
  • the RNA molecule is incubated in the buffer from about 0.01 seconds to about 48 hours.
  • the RNA molecule is incubated in the buffer from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours.
  • the RNA molecule is incubated in the buffer at a specified temperature, for example, from about 4° C to about 75° C.
  • a specified temperature for example, from about 4° C to about 75° C.
  • the RNA molecule is incubated in the buffer at a temperature of about 4° C, about 10° C, about 15° C, about 20° C, about 25° C, about 30° C, about 37, about 40° C, about 45° C, about 50° C, about 55° C, about 60° C, about 65° C, about 70° C, about 75° C or greater than 75° C.
  • the temperature conditions will be selected so as to promote activity of the reverse transcriptase enzyme.
  • An example of a temperature profile for the reverse transcription reaction and inactivation step is shown by FIG. 29.
  • the temperature of the RNA containing sample is heated to a temperature suitable for the RT reaction (T RT ).
  • T RT is reached by a first time (tl) and maintained for a period of time suitable to complete the reaction (ti to t 2 ).
  • T inact a temperature sufficient to inactivate the RT enzyme
  • the sample is maintained at this temperature from time t 3 to time t 4 , which provides a suitable amount of time to inactive the RT enzyme at a temperature of Tinact-
  • the presence of the reverse transcriptase in the buffer may affect or interfere with downstream applications.
  • an additional incubation step may be performed to, for example, destroy or inactivate the reverse transcriptase enzyme.
  • the subsequent incubation step may be from about 0.01 seconds to about 48 hours.
  • the mixture of RNA and DNA molecules produced by the reverse transcriptase step is incubated from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours.
  • the additional incubation step may occur at a temperature between about 57° C and about 100° C.
  • the additional incubation step may occur at a temperature of about 57° C, about 58° C, about 59° C, about 60° C, about 61° C, about 62° C, about 63° C, about 64° C, about 65° C, about 66° C, about 67° C, about 68° C, about 69° C, about 70° C, about 71° C, about 72° C, about 73° C, about 74° C, about 75° C, about 76° C, about 77° C, about 78° C, about 79° C, about 80° C, about 81° C, about 82° C, about 83° C, about 84° C, about 85° C, about 86° C, about 87° C, about 88° C, about 89° C, about 90° C, about 91° C, about 92° C, about 93°
  • the biological sample can be a tissue sample.
  • the tissue sample is a blood sample.
  • the biological sample comprises a bodily fluid taken from a subject.
  • the bodily fluid comprises one or more cells comprising nucleic acids.
  • the one or more cells comprise one or more microbial cells, including, but not limited to, bacteria, archaebacteria, protists, and fungi.
  • the biological sample includes one or more virus particles.
  • the biological sample includes one or more RNA based virus particles.
  • the biological sample comprises one or more microbes that causes a sexually-transmitted disease.
  • a sample may comprise a sample from a subject, such as whole blood; blood products; red blood cells; white blood cells; buffy coat; swabs; urine; sputum; saliva; semen; lymphatic fluid; endolymph; perilymph; gastric juice; bile; mucus; sebum; sweat; tears; vaginal secretion; vomit; feces; breast milk; cerumen; amniotic fluid; cerebrospinal fluid; peritoneal effusions; pleural effusions; biopsy samples; fluid from cysts; synovial fluid; vitreous humor;
  • a sample may comprise cells of a primary culture or a cell line.
  • cell lines include, but are not limited to 293 -T human kidney cells, A2870 human ovary cells, A431 human epithelium, B35 rat neuroblastoma cells, BHK-21 hamster kidney cells, BR293 human breast cells, CHO Chinese hamster ovary cells, CORL23 human lung cells, HeLa cells, or Jurkat cells.
  • the sample may comprise a homogeneous or mixed population of microbes, including one or more of viruses, bacteria, protists, monerans, chromalveolata, archaea, or fungi.
  • the biological sample can be a urine sample, a vaginal swab, a cervical swab, an anal swab, or a cheek swab.
  • the biological sample can be obtained from a hospital, laboratory, clinical or medical laboratory.
  • the sample can be obtained from a subject.
  • sample sources include environmental sources, industrial sources, one or more subjects, and one or more populations of microbes.
  • environmental sources include, but are not limited to agricultural fields, lakes, rivers, water reservoirs, air vents, walls, roofs, soil samples, plants, and swimming pools.
  • industrial sources include, but are not limited to clean rooms, hospitals, food processing areas, food production areas, food stuffs, medical laboratories, pharmacies, and pharmaceutical compounding centers.
  • subjects from which polynucleotides may be isolated include multicellular organisms, such as fish, amphibians, reptiles, birds, and mammals.
  • mammals examples include primates (e.g., apes, monkeys, gorillas), rodents (e.g., mice, rats), cows, pigs, sheep, horses, dogs, cats, or rabbits.
  • rodents e.g., mice, rats
  • cows, pigs, sheep, horses, dogs, cats, or rabbits examples include primates (e.g., mice, rats), cows, pigs, sheep, horses, dogs, cats, or rabbits.
  • the mammal is a human.
  • the sample is from an individual subject.
  • the biological sample is provided in a sample buffer.
  • the sample buffer comprises bovine serum albumin and/or a detergent.
  • the sample buffer comprises about 0.1% to 5% bovine serum albumin.
  • the sample buffer comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin.
  • the sample buffer comprises about 0.1% to 20% detergent.
  • the sample buffer comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent.
  • the detergent is Tween-20.
  • the choice of sample buffer to be used may depend on the intended method. For example the choice of sample buffer may different when a wash step will be used to when a wash step is not used. If a wash step will not be used then the sample buffer may be a buffer suitable for lysis and subsequent PCR reactions.
  • Some commercial collection mediums or sample buffers contain chemicals for the preservation of microorganisms for future growth, or chemicals that lyse target organisms such as guanidinium thiocyanate. As such, these collection media are inhibitory to DNA polymerase and must be washed from a sample before PCR via filtration or similar process. The methods described herein may not require the target organism to be kept in a viable state, or for the sample buffer to be able to lyse the cells.
  • Some components which may be found in a sample buffer suitable for use with the methods and devices of this disclosure include: Tris HCL, Tween-80, BSA, Proclin and Antifoam SE-15.
  • a sample buffer may have a composition of: 50 mM Tris pH 8.4, Tween-80, 2% (w/v), BSA, 0.25% (w/v), Proclin 300, 0.03% (w/v), and Antifoam SE-15, 0.002%) (v/v) made up in purified water.
  • Tris HCL is a common buffer for PCR. When it is heated during thermocy cling, the pH may drop, for example a Tris buffer with pH of 8.4 at a temperature of 25°C may drop to a pH of about -7.4 when heated to about 95°C.
  • the range of concentrations could be from 0.1 mM to 1 M.
  • the pH range could be from 6 to 10.
  • Any other PCR compatible buffer could be used, for example HEPES.
  • Tween-80 is a nonionic surfactant and emulsifier that may help to elute target organisms off of a swab.
  • the range of concentrations could be from 0.01% (w/v) to 20% (w/v). Any other PCR compatible surfactant and/or emulsifier could be used.
  • Proclin 300 is a broad spectrum antimicrobial used as a preservative to ensure a long shelf life of the collection media. It could be used from 0.01% (w/v) to 0.1% (w/v). Many other antimicrobials are known in the art and could be used in a sample buffer.
  • Antifoam SE-15 is present to reduce foaming during manufacturing and fluidic movement through the device. It could be used from 0.001% (v/v) to 1% (v/v). Any other antifoam agent could also be used, for example Antifoam 204, Antifoam A, Antifoam B, Antifoam C, or Antifoam Y-30.
  • the devices and methods provided herein may be utilized to prepare nucleic acids for downstream applications.
  • the downstream applications may be utilized to, e.g., detect the presence or absence of a nucleic acid sequence present in the sample.
  • the devices and methods can be utilized to detect the presence or absence of one or more microbes in a biological sample.
  • the one or more microbes are pathogens (i.e., disease-causative).
  • the one or more microbes are infectious.
  • the one or more microbes cause disease in a subject.
  • the disease is a sexually transmitted disease.
  • the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more bacterial cells in the biological sample.
  • one or more bacterial cells are pathogens.
  • the one or more bacterial cells are infectious.
  • Non-limiting examples of bacterial pathogens that can be detected include Mycobacteria (e.g. M. tuberculosis, M. bovis, M. avium, M. leprae, andM. africanum), rickettsia, mycoplasma, chlamydia, and legionella.
  • bacterial infections include, but are not limited to, infections caused by Gram positive bacillus (e.g., Listeria, Bacillus such as Bacillus anthracis, Erysipelothrix species), Gram negative bacillus (e.g., Bartonella, Brucella,
  • Gram positive bacillus e.g., Listeria, Bacillus such as Bacillus anthracis, Erysipelothrix species
  • Gram negative bacillus e.g., Bartonella, Brucella
  • Campylobacter Enterobacter, Escherichia, Francisella, Hemophilus, Klebsiella, Morganella, Proteus, Providencia, Pseudomonas, Salmonella, Serratia, Shigella, Vibrio and Yersinia species), spirochete bacteria (e.g., Borrelia species including Borrelia burgdorferi that causes Lyme disease), anaerobic bacteria (e.g., Actinomyces and Clostridium species), Gram positive and negative coccal bacteria, Enterococcus species, Streptococcus species, Pneumococcus species, Staphylococcus species, and Neisseria species.
  • spirochete bacteria e.g., Borrelia species including Borrelia burgdorferi that causes Lyme disease
  • anaerobic bacteria e.g., Actinomyces and Clostridium species
  • Gram positive and negative coccal bacteria Enterococcus species, Streptoc
  • infectious bacteria include, but are not limited to: Helicobacter pyloris, Legionella pneumophilia, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium kansaii, Mycobacterium gordonae,
  • Staphylococcus aureus Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Group B
  • Streptococcus Streptococcus
  • Streptococcus viridans Streptococcus faecalis
  • Streptococcus bovis Streptococcus pneumoniae
  • Haemophilus influenzae Bacillus antracis, Erysipelothrix rhusiopathiae, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema perum, Leptospira, Rickettsia, and Actinomyces israelii, Acinetobacter, Bacillus, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Haemophilus, Heli
  • the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more viruses in the biological sample.
  • types of viruses include double stranded DNA viruses, single stranded DNA viruses, double stranded RNA viruses, or single stranded RNA viruses.
  • Single stranded RNA viruses may replicate directly or may include a DNA intermediate in their lifecycle.
  • DNA viruses may replicate directly or through an RNA intermediate.
  • viruses include the herpes virus (e.g., human cytomegalomous virus (HCMV), herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus), influenza A virus and Hepatitis C virus (HCV) or a picornavirus such as Coxsackievirus B3 (CVB3).
  • HCMV human cytomegalomous virus
  • HSV-1 herpes simplex virus 1
  • HSV-2 herpes simplex virus 2
  • VZV varicella zoster virus
  • Epstein-Barr virus Epstein-Barr virus
  • Other viruses may include, but are not limited to, the hepatitis B virus, HIV, poxvirus, hepadavirus, retrovirus, and RNA viruses such as flavivirus
  • viruses examples include, but are not limited to, viruses that are members of the hepadnavirus family, herpesvirus family, iridovirus family, poxvirus family, flavivirus family, togavirus family, retrovirus family, coronavirus family, filovirus family, rhabdovirus family, bunyavirus family, orthomyxovirus family, paramyxovirus family, and arenavirus family.
  • HBV Hepadnavirus hepatitis B virus
  • woodchuck hepatitis virus woodchuck hepatitis virus
  • Hepadnaviridae Hepatitis virus
  • duck hepatitis B virus heron hepatitis B virus
  • Herpesvirus herpes simplex virus (HSV) types 1 and 2 varicella- zoster virus, cytomegalovirus (CMV), human cytomegalovirus (HCMV), mouse cytomegalovirus (MCMV), guinea pig cytomegalovirus (GPCMV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV variants A and B), human herpes virus 7 (HHV-7), human herpes virus 8 (HHV-8), Kaposi's sarcoma - associated herpes virus (KSHV), B virus Poxvirus vaccinia virus, variola virus, smallpox virus, monkeypox virus, cowpox virus, camelpo
  • HSV
  • VEE Venezuelan equine encephalitis
  • chikungunya virus chikungunya virus, Ross River virus, Mayaro virus, Sindbis virus, rubella virus
  • Retrovirus human immunodeficiency virus HIV
  • HTLV human T cell leukemia virus
  • MMTV mouse mammary tumor virus
  • RSV Rous sarcoma virus
  • lentiviruses coronavirus
  • Coronavirus severe acute respiratory syndrome
  • SARS severe acute respiratory syndrome
  • Filovirus Ebola virus Marburg virus
  • Metapneumoviruses such as human metapneumovirus (HMPV), Rhabdovirus rabies virus, vesicular stomatitis virus, Bunyavirus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, La Crosse virus, Hantaan virus, Orthomyxovirus, influenza virus (types A, B, and C), Paramyxovirus, parainfluenza virus (PIV types 1, 2
  • the virus is a non-enveloped virus, examples of which include, but are not limited to, viruses that are members of the parvovirus family, circovirus family, polyoma virus family, papillomavirus family, adenovirus family, iridovirus family, reovirus family, birnavirus family, calicivirus family, and picornavirus family.
  • BFDV Beak and Feather Disease virus, chicken anaemia virus, Polyomavirus, simian virus 40 (SV40), JC virus, BK virus, Budgerigar fledgling disease virus, human papillomavirus, bovine papillomavirus (BPV) type 1, cotton tail rabbit papillomavirus, human adenovirus (HAdV-A, HAdV-B, HAdV-C, HAdV-D, HAdV-E, and HAdV-F), fowl adenovirus A, bovine adenovirus D, frog adenovirus, Reovirus, human orbivirus, human coltivirus, mammalian orthoreovirus, bluetongue virus, rotavirus A, rotaviruses (groups B to G), Colorado tick fever virus, aquareo
  • Calicivirus Calicivirus, swine vesicular exanthema virus, rabbit hemorrhagic disease virus, Norwalk virus, Sapporo virus, Picornavirus, human polioviruses (1- 3), human coxsackieviruses Al-22, 24 (CAl-22 and CA24, CA23 (echovirus 9)), human coxsackieviruses (Bl-6 (CBl-6)), human echoviruses 1-7, 9, 11-27, 29-33, vilyuish virus, simian enteroviruses 1-18 (SEV1-18), porcine enteroviruses 1-11 (PEVl-11), bovine enteroviruses 1-2 (BEV1-2), hepatitis A virus, rhinoviruses, hepatoviruses, cardio viruses, aphthoviruses and echoviruses.
  • the virus may be phage.
  • phages include, but are not limited to T4, T5, ⁇ phage, T7 phage, G4, PI, ⁇ 6, Thermoproteus tenax virus 1, M13, MS2, QJ3, ⁇ 174, ⁇ 29, PZA, ⁇ 15, BS32, B103, M2Y (M2), Nf, GA-1, FWLBcl, FWLBc2, FWLLm3, B4.
  • the virus is selected from a member of the Flaviviridae family (e.g., a member of the Flavivirus, Pestivirus, and Hepacivirus genera), which includes the hepatitis C virus, Yellow fever virus; Tick-borne viruses, such as the Gadgets Gully virus, Kadam virus, Kyasanur Forest disease virus, Langat virus, Omsk hemorrhagic fever virus, Powassan virus, Royal Farm virus, Karshi virus, tick-borne encephalitis virus, Neudoerfl virus, Sofjin virus, Louping ill virus and the Negishi virus; seabird tick-borne viruses, such as the Meaban virus, Saumarez Reef virus, and the Tyuleniy virus; mosquito-borne viruses, such as the Aroa virus, dengue virus, Kedougou virus, Cacipacore virus, Koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St.
  • Tick-borne viruses such as the Gadgets Gully virus, Ka
  • the virus is selected from a member of the Arenaviridae family, which includes the Ippy virus, Lassa virus (e.g., the Josiah, LP, or GA391 strain), lymphocytic choriomeningitis virus (LCMV), Mobala virus, Mopeia virus, Amapari virus, Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Oliveros virus, Parana virus, Pichinde virus, Pirital virus, Sabia virus, Tacaribe virus, Tamiami virus, Whitewater Arroyo virus, Chapare virus, and Lujo virus.
  • the virus is selected from a member of the Bunyaviridae family (e.g., a member of the Hantavirus, Nairovirus,
  • Orthobunyavirus and Phlebovirus genera
  • Hantaan virus Sin Nombre virus
  • Dugbe virus Dugbe virus
  • Bunyamwera virus Rift Valley fever virus
  • La Crosse virus La Crosse virus
  • Punta Toro virus Punta Toro virus
  • California encephalitis virus California encephalitis virus
  • CCHF Crimean-Congo hemorrhagic fever
  • the virus is selected from a member of the Filoviridae family, which includes the Ebola virus (e.g., the Zaire, Sudan, Ivory Coast, Reston, and Kenya strains) and the Marburg virus (e.g., the Angola, Ci67, Musoke, Popp, Ravn and Lake Victoria strains); a member of the Togaviridae family (e.g., a member of the Alphavirus genus), which includes the Venezuelan equine encephalitis virus (VEE), Eastern equine encephalitis virus (EEE), Western equine encephalitis virus (WEE), Sindbis virus, rubella virus, Semliki Forest virus, Ross River virus, Barmah Forest virus, O' nyong'nyong virus, and the chikungunya virus; a member of the Poxyiridae family (e.g., a member of the Ebola virus (e.g., the Zaire, Sudan, Ivory Coast, Reston, and
  • Orthopoxvirus genus which includes the smallpox virus, monkeypox virus, and vaccinia virus
  • a member of the Herpesviridae family which includes the herpes simplex virus (HSV; types 1, 2, and 6), human herpes virus (e.g., types 7 and 8), cytomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella-Zoster virus, and Kaposi's sarcoma associated-herpesvirus (KSHV)
  • a member of the Orthomyxoviridae family which includes the influenza virus (A, B, and C), such as the H5N1 avian influenza virus or HlNl swine flu
  • a member of the Coronaviridae family which includes the severe acute respiratory syndrome (SARS) virus
  • a member of the Rhabdoviridae family which includes the rabies virus and vesicular stomatitis virus (VSV); a member of the Paramyxovirida
  • the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more fungi in the biological sample.
  • infectious fungal agents include, without limitation Aspergillus, Blastomyces, Coccidioides, Cryptococcus, Histoplasma, Paracoccidioides, Sporothrix, and at least three genera of
  • Zygomycetes The above fungi, as well as many other fungi, can cause disease in pets and companion animals.
  • the present teaching is inclusive of substrates that contact animals directly or indirectly. Examples of organisms that cause disease in animals include Malassezia furfur, Epidermophyton floccosur, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton tonsurans, Trichophyton equinum, Dermatophilus congolensis, Microsporum canis, Microsporu audouinii, Microsporum gypseum, Malassezia ovale, Pseudallescheria, Scopulariopsis, Scedosporium, and Candida albicans.
  • fungal infectious agent examples include, but are not limited to, Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, Paracoccidioides brasiliensis, Sporothrix schenckii, Zygomycetes spp., Absidia corymbifera, Rhizomucor pusillus, or Rhizopus arrhizus.
  • the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more parasites in the biological sample.
  • parasites include Plasmodium, Leishmania, Babesia, Treponema, Borrelia, Trypanosoma, Toxoplasma gondii, Plasmodium falciparum, P. vivax, P. ovale, P. malariae, Trypanosoma spp., or Legionella spp.
  • the parasite is Trichomonas vaginalis.
  • the biological sample can be an environmental sample comprising medium such as water, soil, air, and the like.
  • the biological sample can be a forensic sample (e.g., hair, blood, semen, saliva, etc.).
  • the biological sample can comprise an agent used in a bioterrorist attack (e.g., influenza, anthrax, smallpox).
  • the biological sample comprises an infectious agent associated with a sexually-transmitted disease (STD) or a sexually-transmitted infection (STI).
  • STDs or STIs and associated infectious agents that may be detected with the devices and methods provided herein may include, Bacterial Vaginosis; Chlamydia (Chlamydia
  • trachomatis Genital herpes (herpes virus); Gonorrhea (Neisseria gonorrhoeae); Hepatitis B (Hepatitis B virus); Hepatitis C (Hepatitis C virus); Genital Warts, Anal Warts, Cervical Cancer (Human Papillomavirus); Lymphogranuloma venereum (Chlamydia trachomatis); Syphilis
  • Trichomoniasis Trichomonas vaginalis
  • Yeast infection Candida
  • Acquired Immunodeficiency Syndrome Human Immunodeficiency Virus
  • the devices and methods described herein may demonstrate improved performance when compared with traditional methods.
  • the devices and methods may result in the extraction and preparation of nucleic acid molecules suitable for use in a polymerase chain reaction (PCR) in a shorter period of time when compared with other methods.
  • the devices and methods may result in the extraction and preparation of nucleic acid molecules suitable for use in a PCR reaction in 20 minutes or less.
  • PCR polymerase chain reaction
  • the extraction and preparation of nucleic acid molecules as described herein may be achieved in about 20 minutes, 19 minutes, 18 minutes, 17 minutes, 16 minutes, 15 minutes, 14 minutes, 13 minutes, 12 minutes, 11 minutes, 10 minutes, 9 minutes, 8 minutes, 7 minutes, 6 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, 1 minute or less than 1 minute.
  • the extraction and preparation of nucleic acid molecules as described herein is achieved in about 5 minutes or less.
  • the method extracts nucleic acid molecules in about 5 minutes or less at a quality sufficient to successfully run a polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • a quality of extracted or prepared nucleic acid sufficient to run a polymerase chain reaction refers to the quantity of extracted or prepared nucleic acid, the purity of the nucleic acid and the shearing of the nucleic acid (average length of nucleic acid molecules).
  • a sufficient quantity of nucleic acid may refer to about 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 ⁇ g.
  • a sufficient quantity may also refer to the concentration of the nucleic acid in the eluted liquid.
  • the concentration of the eluted nucleic acid may be about 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1 ⁇ g/ ⁇ L.
  • the nucleic acid produced may comprise nucleic acid fragments with an average length of at least about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more than 1000 base pairs.
  • a quality of extracted or prepared nucleic acid sufficient to run a polymerase chain reaction may be a sample that produces at least 70% efficiency as determined by a qPCR standard curve.
  • the efficiency of the PCR may be between 90-100% (-3.6 > slope > -3.3).
  • Efficiency of qPCR may be quantified by calculating the cycle difference between a sample and 10-fold dilution of the sample. For example if the efficiency is 100%, the Ct values of a 10 fold dilution of input DNA will be 3.3 cycles apart (there is a 2-fold change for each change in Ct).
  • the nucleic acid sample extracted or prepared using the devices and methods described herein have similar or improved purity as compared to nucleic acid samples prepared using other methods.
  • the purity may be measured, for example, as a ratio of the absorbance at 260 nm and 280 nm (e.g., A260/A280).
  • a nucleic acid samples comprising DNA prepared using the devices and methods may have a A260/A280 ratio of about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0.
  • the extracted or prepared nucleic acid molecules comprise DNA and the DNA has an A260/A280 ratio of at least 1.5.
  • a nucleic acid sample comprising RNA prepared using the devices and methods may have an A260/A280 ratio of about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, or about 2.2.
  • the extracted nucleic acid molecules comprise RNA and the RNA has an A260/A280 ratio of at least 1.7.
  • Downstream processes such as polymerase chain reaction (PCR) may be sensitive to certain molecules present in a sample.
  • PCR polymerase chain reaction
  • the presence of one or more lysis reagents e.g., Proteinase K
  • the nucleic acid molecules described herein are extracted from the one or more biological cells or entities with a quality that is sufficient to successfully perform one or more downstream processes.
  • the extracted nucleic acid molecules may be of a quality sufficient to successfully perform a PCR.
  • the extracted nucleic acid molecules may be of a quality sufficient to perform an amplification reaction on a target nucleic acid molecule present in the extracted nucleic acid molecules to generate amplified target nucleic molecules.
  • a positive control may be used (e.g., a biological cell that is known to be positive for the target molecule) to confirm that the extraction process is performed successfully.
  • the extracted nucleic acid molecules described herein are generally substantially free of molecules that inhibit downstream processes (e.g., Proteinase K).
  • nucleic acid samples may have similar or improved yields as compared to nucleic acid samples prepared using other methods from the same amount of starting material.
  • nucleic acid samples prepared using the methods and devices described herein may have about 5%, about 10%, about 15%, about 20%, about 25%, about 30%>, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%), about 85%, about 90%, about 95%, about 99% or greater yields than using other nucleic acid extraction methods from the same amount of starting material.
  • Standard nucleic acid extraction methods may involve the use of centrifuges and vacuums. In some cases, the methods and devices herein do not involve the use of centrifuges or vacuums.
  • FIG. 10 is a schematic illustration of a molecular diagnostic test device 1000 (also referred to as a "test device” or “device”), according to an embodiment.
  • the schematic illustration describes the primary components of the test device 1000 as shown in FIG. 11.
  • the test device 1000 is an integrated device (i.e., the modules are contained within a single housing) that is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like), decentralized test facility, or at the user's home.
  • a point-of-care setting e.g., doctor's office, pharmacy or the like
  • the device 1000 can have a size, shape and/or weight such that the device 1000 can be carried, held, used and/or manipulated in a user's hands (i.e., it can be a "handheld" device).
  • a handheld device may have dimensions less than 15cmxl5cmxl5cm, or less than 15cmxl5cmxl0cm, or less than 12cmxl2cmx6cm .
  • the test device 1000 can be a self-contained, single-use device. In some
  • test device 1000 can be configured with lock-outs or other mechanisms to prevent re-use or attempts to re-use the device.
  • the device 1000 can be a CLIA-waived device and/or can operate in accordance with methods that are CLIA waived.
  • the device 1000 (and any of the other devices shown and described herein) is configured to be operated in a sufficiently simple manner, and can produce results with sufficient accuracy to pose a limited likelihood of misuse and/or to pose a limited risk of harm if used improperly.
  • the device 1000 (and any of the other devices shown and described herein), can be operated by a user with minimal (or no) scientific training, in accordance with methods that require little judgment of the user, and/or in which certain operational steps are easily and/or automatically controlled.
  • the molecular diagnostic test device 1000 can be configured for long term storage in a manner that poses a limited likelihood of misuse (spoilage of the reagent(s), expiration of the reagents(s), leakage of the reagent(s), or the like). In some embodiments, the molecular diagnostic test device 1000 is configured to be stored for up to about 36 months, up to about 32 months, up to about 26 months, up to about 24 months, up to about 20 months, up to about 18 months, or any values there between.
  • the test device 1000 is configured to manipulate a biological sample SI to produce one or more output signals associated with a target cell.
  • the device 1000 includes a sample preparation module 1200, an inactivation module 1300 (also referred to as a lysing module), a fluidic drive (or fluid transfer) module 1400, a mixing chamber 1500, an amplification module, a detection module and a power and control module (not shown).
  • the test device and certain components therein can be similar to any of the molecular test devices shown and described herein or in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing," which is incorporated herein by reference in its entirety.
  • modules e.g., the fluidic drive module 1400
  • a description of each of the modules is provided below.
  • FIG. 11 shows a perspective exploded view of the molecular diagnostic test device 1000.
  • the diagnostic test device 1000 includes a housing (including a top portion 1010 and a bottom portion 1030), within which the modules described herein are contained. Similarly stated, the housing (including the top portion 1010 and/or the bottom portion 1030) surround and/or enclose the modules. As shown, the top housing 1010 defines a detection opening 1011 that is aligned with the detection module 1800 such that the signal produced by and/or on each detection surface of the detection module 1800 is visible through the detection opening 1011.
  • the top housing 1010 and/or the portion of the top housing 1010 surrounding the detection opening 1011 is opaque (or semi-opaque), thereby "framing" or accentuating the detection openings.
  • the top housing 1010 can include markings (e.g., thick lines, colors or the like) to highlight the detection opening 1011.
  • the top housing 1010 can include indicia identifying the detection opening to a specific disease (e.g., Chlamydia trachomatis (CT), Neisseria gonorrhea (NG) and Trichomonas vaginalis (TV)) or control.
  • CT Chlamydia trachomatis
  • NG Neisseria gonorrhea
  • TV Trichomonas vaginalis
  • the top housing 1010 can include a series of color spots having a range of colors associated with a range of colors that is likely produced by the signals produced during the test. In this manner, the housing design can contribute to reducing the amount of user judgment required to accurately read the test.
  • the sample preparation module 1200 includes a sample input module 1170, a wash module 1210, an elution module 1260, a filter assembly 1230, and various fluidic conduits (e.g., tubes, lines, valves, etc.) connecting the various components.
  • the device 1000 also includes the lysing module 1300 (see e.g., the lysing module 2300 shown in FIGS. 13- 16), which, together with the sample preparation module 1200, performs the nucleic acid extraction according to any of the methods described herein.
  • the sample preparation module 1200 and the inactivation module 1300 are described as two separate modules, in other
  • the structure and function of the sample preparation module 1200 can be included within or performed by the inactivation module 1300 and vice-versa.
  • any of the sample preparation modules, inactivation modules and/or lysing modules described herein can include any of the structure and/or perform any of the functions of the other modules to perform any of the methods of sample preparation or nucleic acid extraction described herein.
  • the device 1000 is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like) or at the user's home, and can receive any suitable biological sample SI .
  • the biological sample SI (and any of the input samples described herein) can be, for example, blood, urine, male urethral specimens, vaginal specimens, cervical swab specimens, and/or nasal swab specimens gathered using a commercially available sample collection kit.
  • the sample input module 1170 is disposed within the housing 1010, and is configured receive a biological sample SI containing a biological entity.
  • the biological sample SI can be any of the sample types described herein, and the biological entity can be any of the entities described herein.
  • the sample input module 1170 defines a sample volume 1174 that can be selectively covered by the cap 1152.
  • the cap 1152 can include seals or other locking members such that it can be securely fastened to the lower housing 1030 (or other portions of the device 1000) and/or can be closed during shipping, after delivery of a sample thereto, or the like.
  • the input port cap 1152 can include an irreversible lock to prevent reuse of the device 1000 and/or the addition of supplemental sample fluids.
  • the wash module 1210 includes a housing that defines a wash volume containing any suitable wash composition.
  • the wash module 1210 can include a gaseous first wash composition (e.g., nitrogen, air, or another inert gas) and a liquid second wash composition.
  • the wash operation can include an "air purge" of the filter assembly 1230. Specifically, when the sample input module 1170 and/or the wash module 1210 is actuated, a serial flow of the first wash composition (gas) followed by the second wash composition (liquid).
  • the amount of liquid constituents from the input sample conveyed to the filter assembly 1230 can be reduced. Said another way, after delivery of the input sample, the filter assembly 1230 will retain the desired sample cells (or organisms) and some amount of residual liquid.
  • the filter assembly 1230 will retain the desired sample cells (or organisms) and some amount of residual liquid.
  • the amount of residual liquid can be minimized.
  • This arrangement can reduce the amount of liquid wash (e.g., the second wash composition) needed to sufficiently prepare the sample particles. Reducing the liquid volume contributes to the reduction size of the device 1000, and also reduces the likelihood of potentially harmful shearing stress when the liquid wash is flowed through the filter assembly 1230.
  • the sample input module 1170 (and any of the sample input modules described herein) and the wash module 1210 (and any of the wash modules described herein) can be actuated by any suitable mechanism to convey the biological sample SI towards the filter assembly 1230 and/or the lysing module 1300 to enable the nucleic acid extraction methods described herein.
  • the sample input module 1170 and the wash module 1210 are actuated by the sample actuator (or button) 1050.
  • the sample actuator 1050 is movably coupled to the housing, and is aligned with and can move a piston or plunger (not shown) within the sample volume 1174 when the sample input module 1170 is actuated.
  • the sample actuator 1050 is a non-electronic actuator that is manually depressed by a user to actuate the sample input module 1170.
  • the sample actuator 1050 can be an electronic actuator.
  • the sample actuator 1050 can include a lock tab (not shown) that is fixedly received within the notch or opening of the housing 1010 to fix the sample actuator 1050 in its second or "actuated" position, as described above. In this manner, the device 1000 cannot be reused after the initial actuation.
  • the sample within the sample volume 1174 is conveyed along with the wash solution(s) from the wash module 1210 towards the filter assembly 1230.
  • the flow of the biological sample SI towards the filter assembly 1230 is shown by the arrow S2 in FIG. 10.
  • the filter assembly 1230 is configured to filter and prepare the biological sample SI (via the sample input operation and the sample wash operation), and to allow a back-flow elution operation to deliver captured particles from the filter membrane and deliver the eluted volume to lysing module 1300.
  • the filter assembly 1230 can be toggled between two configurations to allow the flow of the biological sample SI and wash solution in a first direction (towards the waste reservoir 1205), followed by a backflush of the elution reagent and the captured organisms (or cells) in a second direction (as indicated by the arrow S3 towards the lysing / inactivation module 1300).
  • the toggling mechanism can be any suitable mechanism, such as those shown and described in
  • the filter assembly 1230 can include any suitable filter membrane that captures the target organism/entity while allowing the bulk of the liquid within the biological sample SI, the first wash composition, and the second wash composition to flow therethrough and into the waste tank 1205.
  • the filter membrane 1254 (and any of the filter membranes described herein) can be any suitable membrane and or combination of membranes as described herein.
  • the filter membrane 1254 is a woven nylon filter membrane with a pore size of about 1 ⁇ (e.g., 0.8 ⁇ , ⁇ . ⁇ , 1.2 ⁇ ) enclosed between various plates of the filter assembly 1230 such that there is minimal dead volume.
  • the elution module (or assembly) 1260 of the sample preparation module 1200 is contained within the housing, and defines an elution volume within which an elution composition is stored.
  • the elution composition can be any of the elution compositions described herein.
  • the elution composition can include proteinase K, which allows for the release of any bound cells and/or nucleic acid molecules (e.g., DNA) from the filter membrane.
  • the output from the elution module 1260 can be selectively placed in fluid communication with the filter assembly 1230, when the filter assembly is toggled into its second (or backflow) configuration.
  • the elution module 1230 can include any suitable flow control devices, such as check valves, duck-bill valves, or the like to prevent flow back towards and/or into the elution volume.
  • the elution module 1210 is actuated by the elution actuator (or button) 1070 (see FIG. 11).
  • the reagent actuator 1070 is movably coupled to the lower housing 1030, and can exert force on a piston or other portion of the elution module 1210 to convey the elution composition back through the filter and towards the lysing module 1300, as shown by the arrow S3.
  • the elution actuator 1070 further includes a lock tab or other structure that is fixedly received within the notch or opening of the housing to fix the elution actuator 1070 in its second or "actuated" position. In this manner, the device 1000 cannot be reused after the actuation of the elution actuator.
  • the filter assembly 1230 recovers the target organisms with a certain efficiency, from a given starting volume.
  • the wash operation then removes undesired material, without removing the target organisms (which stay present on the filter membrane).
  • the elution operation then removes the target organism from the filter membrane, diluting the total amount of captured organisms in the volume of the elution solution, thus comprising the eluent.
  • a further dilution can be achieved, if desired, by mixing the eluent solution with another reagent after the initial sample preparation. Given a known volume of eluent, and a known volume of diluent, a correct dilution factor can be achieved, through to maintain the reliability of the system very high dilution factors are avoided.
  • the elution solution and the captured cells and/or organisms are conveyed during the elution operation back through the filter assembly 1230, and to the inactivation module (or lysing module) 1300.
  • the elution step may involve the nucleic acids, cells, or biological entities passing through the filter.
  • the elution step may involve washing the nucleic acids, cells, or biological entities off the filter, such that they remain on the same side of the filter without passing through it.
  • the inactivation module 1300 is configured to be fluidically coupled to and receive the eluted sample S3 from the sample preparation module 1200.
  • the inactivation module 1300 is configured for lysis of the received input fluid. In some embodiments, the inactivation module 1300 is configured for de-activating the enzymes present in input fluid after lysis occurs. In some embodiments, the inactivation module 1300 is configured for preventing cross-contamination between the output fluid and the input fluid.
  • the inactivation module 1300 can include any of the inactivation (or lysing) modules as described herein, including the lysing module 3300 and the lysing module 4300 described herein.
  • the sample is transferred from the inactivation module to a reverse transcription module 1900.
  • the reverse transcription module is configured to incubate the sample at a temperature suitable for a reverse transcription enzyme, and subsequently incubate the sample at a temperature high enough to deactivate the reverse transcriptase enzyme.
  • the reverse transcription module 1900 may include any of the reverse transcription modules described herein.
  • the reverse transcription module 1900 is omitted from the device and a reverse transcriptase enzyme is present in the amplification module or the mixing module.
  • the reverse transcriptase enzyme is chosen to be one which is active under the conditions required for the amplification reaction.
  • the DNA polymerase enzyme may be chosen for activity under the conditions required by the reverse transcriptase enzyme.
  • the amplification module is capable of heating the solution to the temperatures required for reverse transcription and inactivation of the reverse transcriptase enzyme, as well as the temperatures required by the DNA polymerase enzyme.
  • the mixing module 1500 mixes the output of inactivation module 1300 with the reagents to conduct a successful amplification reaction. Similarly stated, the mixing module 1500 is configured to reconstitute the reagent in a
  • the mixing chamber module 1500 is configured to produce and/or convey a sufficient volume of liquid for the amplification module 1600 to provide sufficient volume output to the detection module 1800.
  • the mixing module 1500 can be any suitable mixing module, such as those shown and described in International Patent Publication No.
  • the fluidic drive (or transfer) module 1400 can be a pump or series of pumps configured to produce a pressure differential and/or flow of the solutions within the diagnostic test device 1000.
  • the fluid transfer module 1400 is configured to generate fluid pressure, fluid flow and/or otherwise convey the biological sample SI, and the reagents through the various modules of the device 1000.
  • the fluid transfer module 1400 is configured to contact and/or receive the sample flow therein.
  • the device 1000 is specifically configured for a single-use to eliminate the likelihood that contamination of the fluid transfer module 1400 and/or the sample preparation module 1200 will become contaminated from previous runs, thereby negatively impacting the accuracy of the results.
  • the fluid transfer module 1500 can be any suitable fluid transfer module, such as those shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing," which is incorporated herein by reference in its entirety.
  • the amplification module 1600 includes a flow member 1610 and a heater 1630.
  • the flow member 1610 can be any suitable flow member that defines a volume or a series of volumes within which the that prepared solution S3 can flow and/or be maintained to amplify the target nucleic acid molecules within the solution S3.
  • the heater 1630 can be any suitable heater or group of heaters coupled to the flow member 1610 that can heat the prepared solution within the flow member 1610 to perform any of the amplification operations as described herein.
  • the amplification module 1600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in U.S. Patent Application No. 15/494, 145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety.
  • the amplification module 1600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
  • the flow member 1610 defines a single volume within which the prepared solution is maintained and heated to amplify the nucleic acid molecules within the prepared solution.
  • the flow member 1610 can define a "switchback" or serpentine flow path through which the prepared solution flows.
  • the flow member 1610 defines a flow path that is curved such that the flow path intersects the heater 1630 at multiple locations. In this manner, the amplification module 1600 can perform a "flow through"
  • the flow member 1610 (and any of the flow members described herein) can be constructed from any suitable material and can have any suitable dimensions to facilitate the desired amplification performance for the desired volume of sample.
  • the amplification module 1600 (and any of the amplification modules described herein) can perform 1000X or greater amplification in a time of less than 15 minutes.
  • the flow member 1610 (and any of the flow members described herein) is constructed from at least one of a cyclic olefin copolymer or a graphite-based material. Such materials facilitate the desired heat transfer properties into the flow path.
  • the flow member 1610 (and any of the flow members described herein) can have a thickness of less than about 0.5 mm. In some embodiments, the flow member 1610 (and any of the flow members described herein) can have a volume about 150 microliters or greater, and the flow can be such that at least 10 microliters of sample is amplified. In other embodiments, at least 20 microliters of sample are amplified by the methods and devices described herein. In other embodiments, at least 30 microliters of sample are amplified by the methods and devices described herein. In yet other embodiments, at least 50 microliters of sample are amplified by the methods and devices described herein.
  • the heater 1630 can be any suitable heater or collection of heaters that can perform the functions described herein to amplify the prepared solution.
  • the heater 1630 can establish multiple temperature zones through which the prepared solution flows and/or can define a desired number of amplification cycles to ensure the desired test sensitivity (e.g., at least 30 cycles, at least 34 cycles, at least 36 cycles, at least 38 cycles, or at least 40 cycles).
  • the heater 1630 (and any of the heaters described herein) can be of any suitable design.
  • the heater 1630 can be a resistance heater, a thermoelectric device (e.g. a Peltier device), or the like.
  • the heater 1630 can be one or more linear "strip heaters" arranged such that the flow path crosses the heaters at multiple different points. In other embodiments, the heater 1630 can be one or more curved heaters having a geometry that corresponds to that of the flow member 1610 to produce multiple different temperature zones in the flow path.
  • the amplification module 1600 is generally described as performing a thermal cycling operation on the prepared solution, in other embodiment, the amplification module 1600 can perform any suitable thermal reaction to amplify nucleic acids within the solution. In some embodiments, the amplification module 1600 (and any of the amplification modules described herein) can perform any suitable type of isothermal amplification process, including, for example, Loop Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA), which can be useful to detect target RNA molecules, Strand
  • LAMP Loop Mediated Isothermal Amplification
  • NASBA Nucleic Acid Sequence Based Amplification
  • SDA Displacement Amplification
  • MDA Multiple Displacement Amplification
  • RAM Ramification Amplification Method
  • the detection methods enabled by the device 1000 include sequential delivery of the detection reagents and other substances within the device 1000. Further, the device 1000 is configured to be an "off-the-shelf product for use in a point-of-care location (or other
  • the reagent storage module 1700 is configured for simple, non-empirical steps for the user to remove the reagents from their long-term storage containers, and for removing all the reagents from their storage containers using a single user action.
  • the reagent storage module 1700 and the rotary selection valve 1340 are configured for allowing the reagents to be used in the detection module 1800, one at a time, without user intervention.
  • the device 1000 is configured such that the last step of the initial user operation (i.e., the depressing of the reagent actuator 1080) results in dispensing the stored reagents.
  • This action crushes and/or opens the sealed reagent containers present in the assembly and relocates the liquid for delivery.
  • the rotary venting selector valve 1340 allows the reagent module 1700 to be vented for this step, and thus allows for opening of the reagent containers, but closes the vents to the tanks once this process is concluded.
  • the reagents remain in the reagent module 1700 until needed in the detection module 1800.
  • the rotary valve 1340 opens the appropriate vent path to the reagent module 1700, and the fluidic drive module 1400 applies vacuum to the output port of the reagent module 1700 (via the detection module 1800), thus conveying the reagents from the reagent module 1700.
  • the reagent module 1700 and the valve 1340 can be similar to the reagent modules and valves shown and described in International Patent Publication No. WO2016/109691, entitled "Devices and Methods for
  • the detection module 1800 is configured to receive output from the amplification module 1600 and reagents from the reagent module 1700 to produce a colorimetric change to indicate presence or absence of target organism in the initial input sample.
  • the detection module 1800 also produces a colorimetric signal to indicate the general correct operation of the test (positive control and negative control). In some embodiments, color change induced by the reaction is easy to read and binary, with no requirement to interpret shade or hue.
  • the detection module 1800 can be similar to the detection modules shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing," which is incorporated herein by reference in its entirety.
  • a device comprising: (a) an input port, configured to receive the biological sample comprising one or more biological cells or biological entities; (b) a filter assembly comprising a filter configured to capture the one or more biological cells or biological entities, wherein the input port is configured to relay the biological sample to the filter assembly; (c) one or more reservoirs comprising a wash solution, a lysis solution, or both, operably coupled to the filter assembly; (d) a waste chamber, operably coupled to the filter assembly and configured to receive waste from the filter assembly; and (e) an elution chamber, operably coupled to the filter assembly and configured to receive an eluent from the filter assembly.
  • FIG. 12 depicts an example of a sample preparation device (or module) 2200 that may be used to perform the methods provided herein.
  • the sample preparation module 2200 can be included in any of the molecular diagnostic test devices described herein, including the device 1000 described above. It should be understood that the invention is not limited to a particular arrangement or configuration of the sample preparation device, and any suitable arrangement or configuration may be used.
  • the sample preparation device 2200 comprises an input port 2170.
  • the input port is configured to receive a sample (e.g., biological sample).
  • the input port 2170 may be configured to receive about 50 ⁇ _, to about 20 mL of a liquid sample.
  • the input port 2170 may comprise a reservoir or chamber for holding or storing the sample.
  • the input port 2170 may comprise a cap or lid (similar to the lid 1152 described above) that can be placed over the input port to contain the sample in the reservoir or chamber.
  • the input port 2170 may be operably coupled to a filter assembly 2230.
  • the sample may be relayed (e.g., pushed or flowed) to the filter assembly 2230 in any manner as described herein.
  • the filter assembly 2230 may contain one or more filter membranes for capturing biological cells or entities on the filter.
  • the filter assembly 2230 (or any of the filter assemblies described herein) contains at least two filter membranes, one with a larger pore size and one with a smaller pore size.
  • the two filter membranes may be arranged such that the sample first passes through the membrane with the larger pore size and then the membrane with the smaller pore size.
  • the filter membrane may be of any suitable material as described herein, non-limiting examples including nylon, cellulose, polyethersulfone (PES), polyvinylidene difluoride (PVDF), polycarbonate, borosilicate glass fiber and the like.
  • the filter membrane is nylon.
  • the filter membrane has an average pore size of about 0.2 ⁇ to about 20 ⁇ .
  • the filter membrane may have an average pore size of about 0.2 ⁇ , about 0.5 ⁇ , about 1 ⁇ , about 2 ⁇ , about 3 ⁇ , about 4 ⁇ , about 5 ⁇ , about 6 ⁇ , about 7 ⁇ , about 8 ⁇ , about 9 ⁇ , about 10 ⁇ , about 11 ⁇ , about 12 ⁇ , about 13 ⁇ , about 14 ⁇ , about 15 ⁇ , about 16 ⁇ , about 17 ⁇ , about 18 ⁇ , about 19 ⁇ , about 20 ⁇ , or greater than 20 ⁇ .
  • the surface of the filter membrane may be chemically treated or coated in such a way as to improve the binding of a biological cell or entity to the membrane.
  • the biological cells or entities may be captured on the membrane while the majority of the liquid (“flow-through") is flowed through the filter membrane.
  • the flow-through is substantially devoid of biological cells or entities.
  • the flow-through is disposed of by relaying the flow-through to one or more waste chambers operably coupled to the filter assembly. In other cases, the flow-through is relayed to a collection chamber for further downstream processing.
  • the sample preparation device 2200 further comprises one or more chambers 2210 or reservoirs for housing a wash solution.
  • the one or more chambers or reservoirs (also referred to as wash modules) housing the wash solution may be operably coupled to the filter assembly such that actuation of the wash chamber or reservoir 2210 relays the wash solution to the filter assembly 2230.
  • the wash solution is provided as a lyophilized pellet or bead that sits within the chamber or reservoir. The lyophilized pellet or bead can be reconstituted in one or more solutions.
  • the wash solution may be flowed through the filter assembly 2230 and the majority of the liquid can be collected in the one or more waste chambers 2205.
  • wash solutions suitable for use with the sample preparation device have been described above.
  • the sample preparation device further comprises one or more chambers or reservoirs for housing a lysis solution.
  • the chamber or reservoir housing the lysis solution may be operably coupled to the filter assembly such that actuation of the chamber or reservoir relays the lysis solution to the filter assembly.
  • the lysis solution may be flowed through the filter assembly.
  • the lysis solution may cause the lysis or disruption of the biological cells or entities on the filter membrane.
  • the reagents of the lysis solution are provided as a lyophilized pellet or bead that sits within the chamber or reservoir (e.g., within a lysing module, similar to the lysing modules 1300, 3300 and 4300 described herein).
  • the lyophilized pellet or bead can be reconstituted in one or more solutions.
  • the lysis enzyme is stored separately as a lyophilized bead or pellet within the device.
  • the lyophilized lysis enzyme may be reconstituted in the lysis buffer prior to addition to the cells.
  • the cells are eluted from the filter membrane and relayed into the elution chamber 2260 which contains the lyophilized lysis enzyme, thereby reconstituting the enzyme.
  • the enzyme is stable in the device at ambient temperatures for long periods of time.
  • the enzyme may be stable in the device at ambient temperature for at least one day, at least two days, at least three days, at least four days, at least five days, at least six days, at least one week, at least two weeks, at least three weeks, at least four weeks, at least a month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, at least one year, at least two years, at least three years, at least four years, at least five years, at least six years, at least seven years, at least eight years, at least nine years, at least ten years or longer.
  • the lysis solution containing the lysed cells (“eluent”) may be collected in an elution chamber.
  • the lysis solution may be back-flowed through the filter assembly.
  • the biological cells or entities on the filter membrane may be pushed or washed from the membrane and collected in an elution chamber with the lysis solution.
  • the cells or entities (or lysed or otherwise disrupted cells or entities) diluted in the lysis solution may be referred to as the "eluent.”
  • the sample preparation device 2200 may further comprise one or more heating modules (not shown).
  • the one or more heating modules may be operably coupled to the elution chamber 2260.
  • the one or more heating modules may heat the elution chamber to a temperature sufficient for lysis of the biological cells or entities to occur.
  • the lysis solution comprises one or more enzymes (e.g., Proteinase K).
  • the one or more heating modules heats the elution chamber to a temperature sufficient for optimal performance of the lysis enzyme.
  • the heating module heats the elution chamber (and the fluid contained therein) to a temperature of about 4° C, about 10° C, about 15° C, about 20° C, about 25° C, about 30° C, about 40° C, about 45° C, about 50° C, about 55° C, about 60° C, about 65° C, about 70° C, about 75° C or greater than 75° C.
  • the sample preparation device 2200 and/or any of the molecular diagnostic devices described herein further comprises an inactivation chamber (also referred to as an inactivation module or a lysing module).
  • the inactivation chamber may be operably coupled to the elution chamber.
  • the eluent may be relayed from the elution chamber to the inactivation chamber.
  • the elution chamber and the inactivation chamber are the same chamber and are coupled to a heating element that can heat the chamber to an optimal lysis temperature, and can further heat the chamber to an optimal inactivation temperature (e.g., from about 56° C to about 95° C).
  • the inactivation chamber comprises a chamber body 3310, a bottom lid 3318, and a heater 3330.
  • the chamber body 3310 may defines an input port 3312, a holding tank (or first volume) 3311, a permanent vent 3314, an inactivation segment (or second volume) 3321, and an output port 3313.
  • the input port 3312 may be configured to receive the eluent from the elution chamber and/or directly from a filter assembly (e.g., the filter assembly 1230).
  • the input port 3312 can be fluidically coupled to a sample input module without the biological input being conveyed through a filter.
  • the eluent may flow into the inactivation chamber (or lysing module 3300) and be collected in the holding tank 3311.
  • the holding tank may have a capacity of about 1 ⁇ . to about 100 mL, about 100 ⁇ . to about 10 mL, about 300 ⁇ L to 1 mL, or about 300 ⁇ L to about 650 ⁇
  • the holding tank may be used to lyse the sample.
  • the eluent containing the target organisms can be heated by the heater 3330 to maintain the eluent at or above a target lysing temperature.
  • the heater 3330 can be coupled to the chamber body 3310 and/or the bottom lid 3318 such that the heater 3330 can convey thermal energy into the lysing module 3300 to produce a lysing temperature zone within the holding tank (or first volume) 3311.
  • the lysing temperature zone can maintain the eluent at any of the temperatures and for any of the time periods described herein.
  • the vent 3314 may be a hole which allows air to flow into or out of the lysing module 3300 (including the first volume 3311 and the second volume 3321) as sample is brought in or out.
  • the vent 3314 can also relieve pressure within either of the first volume 3311 or the second volume 3321 when the eluent is heated.
  • the lysing module 3300 (or any of the lysing modules described herein) can have an active vent.
  • the lysing module 3300 (or any of the lysing modules described herein) can include a valve that controls the venting of pressure and/or air from within the lysing module 3300.
  • the eluent may flow from the holding tank 3311 through the inactivation segment of the lysing module 3300. More specifically, the holding tank 3311 is in fluid communication with the inactivation segment 3321 such that when a pressure gradient is applied across the input port 3312 and the output port 3313, the eluent can flow from the holding tank 3311 (first volume) through the inactivation segment 3321 (second volume).
  • the pressure gradient can be applied by any suitable mechanism, such as for example, a pump (e.g., the fluidic drive module 1400).
  • the inactivation segment 3321 may be a small, shallow channel that allows efficient and rapid heating of the eluent as it leaves the holding tank.
  • the inactivation segment 3321 is configured in a serpentine pattern.
  • the serpentine pattern may allow for rapid inactivation of the lysis enzymes in the eluent.
  • the eluent after being flowed through the inactivation segment, may be flowed into the output port 3313 to be collected.
  • the volume of liquid passed through the heated channel could be from about 1 ⁇ . to about 100 mL, about 10 ⁇ . to about 10 mL, about 100 to about 5 mL, or about 250 ⁇ L to about 750 ⁇ L.
  • the inactivation module 3300 may be in contact with a heating element 3330, which can be, for example, a printed circuit board (PCB) heater.
  • the heating element 3330 may function to heat the eluent as it flows through the inactivation segment at a high temperature sufficient to inactivate the one or more lysis enzymes contained within the eluent.
  • the heating element may heat the eluent to about 57° C, about 58° C, about 59° C, about 60° C, about 61° C, about 62° C, about 63° C, about 64° C, about 65° C, about 66° C, about 67° C, about 68° C, about 69° C, about 70° C, about 71° C, about 72° C, about 73° C, about 74° C, about 75° C, about 76° C, about 77° C, about 78° C, about 79° C, about 80° C, about 81° C, about 82° C, about 83° C, about 84° C, about 85° C, about 86° C, about 87° C, about 88° C, about 89° C, about 90° C, about 91° C, about 92° C, about 93° C, about 94° C , about 95° C, about 96° C, about 97° C, about 98
  • the lysis enzymes as well as any other enzymes present can be deactivated.
  • the sample can be heated to about 95 C for about 3 minutes.
  • the serpentine path 3321 may be preceded by a check valve (not shown) to maintain a back pressure such that fluid does not enter the serpentine path 3321 before the desired temperature has been achieved.
  • the serpentine area may be preheated to the desired temperature (50°C to 99°C or more) before fluid is drawn through the serpentine channel. If fluid were to flow into the serpentine channel prematurely without controlled flow, large bubbles may form in the channel as the heater warms up which could result in portions of the fluid to pass through the channel without receiving the proper temperature treatment.
  • the cracking pressure may be from 0.05 to 50 psi. In some examples, the check valves used may have a cracking pressure of approximately 0.5 psi.
  • the solution within the second volume 3321 is rapidly heated to temperatures of up to about 100 degrees Celsius.
  • the lysing module 3300 and/or the formulation of the input solution e.g., the eluent
  • the lysing module 3300 and/or the formulation of the input solution can collectively reduce the likelihood that the liquid portion of the input solution will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher.
  • the input solution can include salts and/or sugars to raise the boiling temperature of the input solution.
  • the lysing module 3300 can include one or more vent openings into either the first volume 331 1 or the second volume 3321 or both (to limit pressure build-up during heating).
  • the output from the lysing module 3300 can be conveyed into an (e.g., the amplification module 1600 or any other amplification modules described herein).
  • the output from the lysing module 3300 which contains the extracted nucleic acid molecules, can be conveyed to an amplification module.
  • the amplification module can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution containing target nucleic acid mixed with required reagents.
  • the amplification module is configured to conduct rapid amplification of an input target.
  • the amplification module is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module (e.g., the detection module 1800).
  • FIGS. 17-22 show various views of a lysing module 4300 (also referred to as an inactivation module), according to an embodiment.
  • the lysing module 4300 includes a chamber body 4310, a bottom lid 4318, a heater 4330, and an electrode assembly.
  • the chamber body 4310 and the bottom lid 4318 can be referred to as a flow member.
  • the flow member is shown as being constructed from two pieces (the body 4310 and the bottom lid 4318) that are coupled together, in other embodiments, the flow member can be monolithically constructed.
  • the chamber body 4310 and the bottom lid 4318 define an input port 4312, a first (or holding) volume 4311, a vent 4314, a second (or inactivation) volume 4321, and an output port 4313.
  • the input port 4312 can receive the eluent from the elution chamber and/or directly from a filter assembly (e.g., the filter assembly 1230).
  • the input port 4312 can be fluidically coupled to a sample input module without the biological input being conveyed through a filter.
  • the eluent can flow into the lysing module 4300 and be collected in the holding volume 4311.
  • the sample can be lysed within the holding volume 4311.
  • the eluent containing the target organisms can be heated by the heater 4330 to maintain the eluent at or above a target lysing temperature.
  • the heater 4330 can be coupled to the chamber body 4310 and/or the bottom lid 4318 such that the heater 4330 can convey thermal energy into the lysing module 4300 to produce a lysing
  • the lysing temperature zone can maintain the eluent at any of the temperatures and for any of the time periods described herein.
  • the vent opening 4314 is in fluid communication with the first volume 4311, and thus allows air to flow into or out of the lysing module 4300 (including the first volume 4311 and the second volume 4321) as sample is conveyed into and/or out of the lysing module 4300.
  • the vent 4314 can also relieve pressure within either of the first volume 4311 or the second volume 4321 when the eluent is heated.
  • the lysing module 4300 can have an active vent.
  • the lysing module 4300 (or any of the lysing modules described herein) can include a valve that controls the venting of pressure and/or air from within the lysing module 4300.
  • the first volume 4311 is in fluid communication with the second volume 4322.
  • the eluent can flow from the first (or holding) volume 4311 through the second (or inactivation) volume 4321 of the lysing module 4300.
  • the pressure gradient can be applied by any suitable mechanism, such as for example, a pump (e.g., the fluidic drive module 1400).
  • the second volume 4321 is a serpentine channel that provides a high surface area to volume ratio. This arrangement allows for rapid inactivation of the lysis enzymes in the eluent.
  • the eluent after being flowed through the inactivation segment, may be flowed into the output port 4313 to be collected and/or conveyed to an amplification module (not shown).
  • the flow member is in contact with a heating element 4330, which can be, for example, a printed circuit board (PCB) heater.
  • the heating element 4330 may function to heat the eluent as it flows through the second volume 4311 at a high temperature sufficient to inactivate the one or more lysis enzymes contained within the eluent.
  • the heating element may heat the eluent to about 57° C, about 58° C, about 59° C, about 60° C, about 61° C, about 62° C, about 63° C, about 64° C, about 65° C, about 66° C, about 67° C, about 68° C, about 69° C, about 70° C, about 71° C, about 72° C, about 73° C, about 74° C, about 75° C, about 76° C, about 77° C, about 78° C, about 79° C, about 80° C, about 81° C, about 82° C, about 83° C, about 84° C, about 85° C, about 86° C, about 87° C, about 88° C, about 89° C, about 90° C, about 91° C, about 92° C, about 93° C, about 94° C , about 95° C, about 96° C, about 97° C, about 98
  • the sample can be heated to about 95 C for about 4 minutes.
  • the heater on the PCB 4330 is specifically designed to heat the serpentine portion of the lysing module 4300 (i.e., the second volume 4321) while not heating the holding volume 4311. Because the lid 4318 of the lysing module 4300 is thick, the heater surface may be heated well above the desired temperature of the fluid. Since the electrodes 1971, 1972 (described in more detail below) are thermally conductive and come into direct contact with the fluid, the fluid surrounding the electrodes 1971, 1972 will experience the same temperature as the heater surface, which may cause evaporation. To minimize the heating of the holding volume 4311, a slot (not shown) may be cut in the PCB 4330 to isolate the heater from the portion of the PCB adjacent and/or in contact with the holding volume 4311. For example, in some
  • the heater 4330 can include a series of slots and/or openings as described in U.S. Patent Application No. 15/494, 145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety. Moreover, in some
  • the heating element of the heater 4330 is located on an internal layer so the top copper pour (not shown) can be used as a heat spreader to minimize temperature variation along the serpentine path.
  • the six wires soldered to the PCB 4330 may remove heat from the surrounding area, creating temperature gradients across the heater surface. To minimize this effect, wires may be soldered on both sides of the heater surface so the temperature roll off is symmetrical.
  • the lysing module 4300 can determine whether there is liquid in the first volume 4311 and/or the second volume 4321. Specifically, the lysing module 4300 includes electrical probes to determine electrical resistance of the fluid within the first volume.
  • the molecular diagnostic device e.g., the device 1000
  • the molecular diagnostic device can include an electronic controller configured to determine when the user has actuated the elution module (e.g., by pressing an elution actuator, similar to the button 1070 described above) by detecting the presence of liquid in the first volume 4311. In this manner, the introduction of liquid into the first volume 4311 can trigger the start of the device.
  • the control system and/or the lysing module 4300 includes two electrodes 4971, 4972 inside the first volume 4311.
  • the electrodes 4971, 4972 are connected to circuitry (e.g., a controller, not shown) that detects a resistance change between the two electrodes 4971, 4972.
  • Fluid may be reliably detected between the electrodes 4971, 4972 due to the high gain of the circuit, which may easily differentiate between an open circuit condition (no fluid) and a non-negligible resistance across the electrodes 4971, 4972 (fluid detected).
  • Use of a sample matrix with high salt concentration increases the conductivity of the fluid, which may make the fluid easily detectable even with variation across samples.
  • the electrodes 4971, 4972 and the circuitry are designed to detect fluid without impacting the biological processes that take place in the device.
  • the electrodes 4971, 4972 are specifically chosen so as not inhibit PCR reactions.
  • the electrodes 4971, 4972 are gold plated.
  • Both DNA and cells have a net charge so they may migrate in the presence of an electric field. Because the resistance change between the electrodes 4971, 4972 is determined by measuring a change in electric potential, precautions may be taken to minimize the impact of this electromotive force. For example, once fluid is detected voltage may be removed from the electrodes 4971, 4972 and they may be electrically shorted together. This ensures there is no potential difference between the electrodes 4971, 4972 and the charged particles (DNA, cells, salts, etc.) will not bind to the electrodes, which would prevent them from entering the amplification module (not shown).
  • the solution within the second volume 4321 is rapidly heated to temperatures of up to about 100 degrees Celsius.
  • the lysing module 4300 and/or the formulation of the input solution e.g., the eluent
  • the lysing module 4300 and/or the formulation of the input solution can collectively reduce the likelihood that the liquid portion of the input solution will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher.
  • the input solution can include salts and/or sugars to raise the boiling temperature of the input solution.
  • the lysing module 4300 can include one or more vent openings into either the first volume 4311 or the second volume 4321 or both (to limit pressure build-up during heating).
  • the reverse transcription module consists of an incubation chamber in which a reverse transcription reaction can take place and a means to heat the sample to a temperature sufficient to deactivate a reverse transcriptase enzyme.
  • the reverse transcriptase may be present as a lyophilized pellet in the incubation chamber of the reverse transcription module. The lyophilized pellet is rehydrated by the sample when the sample enters 1900, thus allowing a reverse transcriptase enzyme.
  • the lyophilized pellet may contain suitable salts to buffer the sample to ensure suitable conditions for the reverse transcriptase enzyme. In some cases the reverse transcription enzyme may be chosen to have activity in the sample without requiring additional buffers.
  • the lyophilized pellet may also contain compounds of additives to stabilize the enzyme in the lyophilized state and preserve enzymatic activity once rehydrated.
  • the lyophilized pellet may contain primers for the reverse transcriptase enzyme.
  • the primers may be specific primers to amplify RNA molecules of specific sequences, random primers such as random hexamers, or primers targeted to common sequences, such as poly T primers to amplify RNA molecules with poly-A tails.
  • the reverse transcription reaction may occur in the incubation chamber of the reverse transcription module 1900.
  • the incubation chamber may be
  • the output from the lysing module 4300 can be conveyed into an (e.g., the amplification module 1600 or any other amplification modules described herein).
  • the output from the lysing module 4300 which contains the extracted nucleic acid molecules, can be conveyed to an amplification module.
  • the amplification module can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution containing target nucleic acid mixed with required reagents.
  • the amplification module is configured to conduct rapid amplification of an input target.
  • the amplification module is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module (e.g., the detection module 1800).
  • a sample preparation device need not include a filter or filter assembly.
  • the sample input may be directly linked to an inactivation chamber, as shown schematically in FIG. 23.
  • Advantages of a device without a filter assembly include lower pressures in the device, no risk of breaking a filter, fewer parts, fewer reagents required, higher recovery of target organisms from the clinical sample matrix and higher recovery of DNA from target organisms.
  • FIG. 23 and FIG. 35 shows a portion of a molecular test device 5000 that includes a sample input module 5170 and an inactivation (or lysing) module 5300. The portion of a molecular test device in FIG.
  • the device 5000 can be similar to the device 1000 described above, and can include an amplification module, a detection module or the like. In this case, the device 5000 differs from the device 1000 in that the sample is flowed from the input module 5170 into the holding tank of the inactivation module 5300.
  • the sample may be lysed either in the holding tank 5311 or in the inactivation segment 5321. In this case the sample may be lysed by heating without need for a specialized lysis buffer or lysis enzymes. Any proteases or nucleases released from the cells of the sample will be inactivated by heating.
  • a sample may be flowed into the holding tank and held until the inactivation segment 5321 reaches a set temperature (for example greater than 90C) and then flowed through the inactivation segment.
  • the sample In the inactivation segment the sample is rapidly heated to 95C causing the cells in the sample to lyse and proteins from within the cells to be inactivated.
  • the sample may be reverse transcribed in the reverse transcription chamber 5611 and the reverse transcriptase enzyme may be inactivated in the inactivation segment 5621.
  • FIG. 24 is a schematic illustration of a molecular diagnostic test device 6000 (also referred to as a "test device” or “device”), according to an embodiment.
  • the test device 6000 includes a housing 6010, a sample input module 6170, a lysing module 6300, and an amplification module 6600.
  • the housing 6010 can be any structure within which the sample input module 6170, the lysing module 6300, and the amplification module 6600 are contained.
  • the test device 6000 can have a size, shape and/or weight such that the device can be carried, held, used and/or manipulated in a user's hands (i.e., it can be a "handheld” device).
  • the test device 6000 can be a self-contained, single-use device of the types shown and described herein (e.g., the device 1000) or in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
  • the sample input module 6170 is disposed within the housing 6010, and is configured receive a biological sample SI containing a biological entity.
  • the biological sample SI can be any of the sample types described herein, and the biological entity can be any of the entities described herein.
  • the sample input module 6170 defines a sample volume 6174, and includes a piston 6180 that is movably disposed within the sample volume 6174.
  • the biological sample SI can be conveyed into the sample volume 6174 by any suitable mechanism, such as, for example, via a pipette, a dropper, or the like.
  • the biological sample SI can be conveyed via an opening into the sample volume 6174 that can be blocked to prevent backflow of the sample back out of the sample input volume 6174.
  • the sample input module 6170 can include any suitable flow control devices, such as check valves, duck-bill valves, or the like, to control the flow of the biological sample SI within the device 6000.
  • the sample input module 6170 (and any of the sample input modules described herein) can be actuated by any suitable mechanism to convey the biological sample SI towards the lysing module 6300 to enable the nucleic acid extraction methods described herein.
  • the sample input module 6170 is actuated by the sample actuator (or button) 6050.
  • the sample actuator 6050 is movably coupled to the housing 6010, and is aligned with and can move the piston 6180 when the sample input module 6170 is actuated.
  • the sample actuator 6050 is a non-electronic actuator that is manually depressed by a user to actuate the sample input module 6170. In other embodiments, however, the sample actuator 6050 can be an electronic actuator.
  • the sample actuator 6050 can include a lock tab (not shown) that is fixedly received within the notch or opening of the housing 6010 to fix the sample actuator 6050 in its second or "actuated" position, as described above. In this manner, the device 6000 cannot be reused after the initial actuation.
  • the piston 6180 is moved downward within the sample volume 6174, as shown by the arrow AA, the sample within the sample volume 6174 is conveyed towards the lysing module 6300.
  • the flow of the biological sample SI towards the lysing module 6300 is shown by the arrow S2 in FIG. 24.
  • the lysing module 6300 (also referred to as the inactivation module), which can be a portion of a sample preparation module, is configured to process the biological sample SI to facilitate detection of an organism therein that is associated with a disease. Specifically, the lysing module 6300 is configured to concentrate and lyse cells in the biological sample SI, thereby allowing subsequent extraction of a nucleic acid to facilitate amplification (e.g., via the
  • the amplification module 6600 and/or detection (e.g., via a detection module, not shown).
  • the processed/lysed sample e.g., the sample S3
  • the lysing module 6300 is pushed and/or otherwise transferred from the lysing module 6300 to other modules within the device 6000 (e.g., the amplification module 6600).
  • the device 6000 is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like) or at the user's home, and can receive any suitable biological sample SI .
  • the biological sample SI (and any of the input samples described herein) can be, for example, blood, urine, male urethral specimens, vaginal specimens, cervical swab specimens, and/or nasal swab specimens gathered using a commercially available sample collection kit.
  • the lysing module includes a flow member 6310 and a heater 6330.
  • the flow member 6310 includes an input port 6312 and an output port 6313, and defines a first volume 6311 and a second volume 6321. As shown, the first volume 6311 can receive an input solution
  • the lysis buffer can be any of the lysis buffers described herein. Moreover, the lysis buffer can be mixed with the biological sample SI to form the input solution S2 in any suitable manner or at any suitable location within the device 6000.
  • the lysis buffer can be stored within the sample input module 6170, and can be mixed with the biological sample SI when the biological sample SI is conveyed into the volume 6174.
  • the lysis buffer can be stored in a reagent module (not shown) and can be mixed with the biological sample SI when the sample input module 6170 is actuated (e.g., via the actuator 6050).
  • the lysis buffer can be stored in the lysing module 6300 (e.g., the first volume 6311).
  • the heater 6330 is coupled to the flow member 6310 and is configured to produce thermal energy that is conveyed into the first volume 6311, the second volume 6321, or both the first volume 6311 and the second volume 6321 to lyse organisms within the biological sample SI and/or the input solution S2.
  • the lysing module 6300 can release one or more nucleic acid molecules from within the cells and/or organisms within the biological sample SI and/or the input solution S2.
  • the heater 6330 and the flow member 6310 are collectively configured to maintain the input solution S2 at a desired lysing temperature for a predetermined amount of time to facilitate and/or promote lysing of the organisms therein.
  • the first volume 6311 and/or the second volume 6321 can be maintained at a temperature between about 55 degrees Celsius and about 600 degrees Celsius for a time period of about 25 seconds or more. In other embodiments, the first volume 6311 and/or the second volume 6321 can be maintained at a temperature between about 92 degrees Celsius and about 98 degrees Celsius.
  • the heater 6330 and the flow member 6310 are configured to heat the first volume 6311, the second volume 6321, or both the first volume 6311 and the second volume 6321 to inactivate enzymes present within the biological sample SI and/or the input solution S2.
  • the lysing module 6300 can denature certain proteins and/or inactivate certain enzymes present within organisms that are within the input solution S2. Such proteins and/or enzymes can, in certain instances, limit the efficiency or effectiveness of the desired amplification operation. Thus, rapid and efficient inactivation can improve the repeatability and accuracy of the amplification and/or the detection of the molecular diagnostic device 6000.
  • the heater 6330 and the flow member 6310 can collectively produce an inactivation temperature zone within which the input solution S2 can be heated to within the desired temperature range and/or for the desired time period to produce the desired inactivation.
  • the input solution S2 within the lysing module 6300 can be maintained at a temperature between about 55 degrees Celsius and about 600 degrees Celsius for a time period of about 25 seconds or more. In other embodiments, the input solution S2 within the lysing module 6300 can be maintained at a temperature between about 92 degrees Celsius and about 98 degrees Celsius.
  • the input solution S2 can be heated to the desired temperature range to both lyse the organisms and inactivate the enzymes as the input solution S2 flows through the first volume 6311 and/or the second volume 6321.
  • the lysing module 6300 can perform "flow through" inactivation and lysing operations. For example, in some
  • either of the first volume 6311 or the second volume 6321 can define a tortuous flow path through which the input solution S2 flows during the lysing / inactivation operation.
  • the surface area-to-volume ratio of the first volume 6311 and/or the second volume 6321 can be high enough such that the heat transfer into the input solution S2 occurs rapidly as it flows through the lysing module.
  • the first volume 6311 and/or the second volume 6321 can define a serpentine flow path.
  • a ratio of the surface area of the second volume 6321 to the volume of the second volume 6321 is 20 cm "1 .
  • the flow member 6310 (and any of the flow members described herein) can have a volume about 650 microliters or greater, and the flow can be such that at least 60 microliters of the input solution S2 is prepared for amplification (i.e., has nucleic acids extracted therefrom). In other embodiments, at least 20 microliters of the input solution S2 is prepared for amplification by the methods and devices described herein. In other embodiments, at least 30 microliters of the input solution S2 is prepared for amplification by the methods and devices described herein. In yet other embodiments, at least 50 microliters of the input solution S2 is prepared for amplification by the methods and devices described herein.
  • the input solution S2 is rapidly heated to temperatures of up to about 100 degrees Celsius.
  • the lysing module 6300 and/or the formulation of the input solution S2 can collectively reduce the likelihood that the liquid portion of the input solution S2 will boil during the lysing / inactivation operations. Such boiling can produce undesirable bubbles and/or air pockets and can reduce the repeatability of the lysing and/or inactivation operations.
  • the lysing module 6300 and/or the formulation of the input solution S2 can collectively reduce the likelihood that the liquid portion of the input solution S2 will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher.
  • the input solution S2 can include salts and/or sugars to raise the boiling temperature of the input solution S2.
  • the lysing module 6300 can include one or more vent openings into either the first volume 6311 or the second volume 6321 or both (to limit pressure build-up during heating). In such embodiments, the vent opening can be such that a limited amount of pressure is allowed within the first volume 6311 or the second volume 6321 to raise the boiling temperature of the input solution S2.
  • the output from the lysing module 6300 can be conveyed into the amplification module 6600.
  • the output from the lysing module 6300 which is identified as the prepared solution S3, and which contains the extracted nucleic acid molecules, can be conveyed to the amplification module 6600.
  • the amplification module 6600 can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution S3 containing target nucleic acid mixed with required reagents.
  • the amplification module 6600 is configured to conduct rapid amplification of an input target.
  • the amplification module 6600 is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module.
  • the amplification module 6600 includes a flow member 6610 and a heater 6630.
  • the flow member 6610 can be any suitable flow member that defines a volume or a series of volumes within which the prepared solution S3 can flow and/or be maintained to amplify the target nucleic acid molecules within the solution S3.
  • the heater 6630 can be any suitable heater or group of heaters coupled to the flow member 6610 that can heat the prepared solution S3 within the flow member 6610 to perform any of the amplification operations as described herein.
  • the amplification module 6600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in U.S. Patent Application No. 65/494, 145, entitled "Printed Circuit Board Heater for an Amplification Module," which is incorporated herein by reference in its entirety.
  • the flow member 6610 defines a single volume within which the prepared solution S3 is maintained and heated to amplify the nucleic acid molecules within the prepared solution S3.
  • the flow member 6610 can define a "switchback" or serpentine flow path through which the prepared solution S3 flows.
  • the flow member 6610 defines a flow path that is curved such that the flow path 6618 intersects the heater 6630 at multiple locations. In this manner, the amplification module 6600 can perform a "flow through" PCR where the prepared solution S3 flows through multiple different temperature regions.
  • the flow member 6610 (and any of the flow members described herein) can be constructed from any suitable material and can have any suitable dimensions to facilitate the desired amplification performance for the desired volume of sample.
  • the amplification module 6600 (and any of the amplification modules described herein) can perform 6000X or greater amplification in a time of less than 65 minutes.
  • the flow member 6610 (and any of the flow members described herein) is constructed from at least one of a cyclic olefin copolymer or a graphite-based material. Such materials facilitate the desired heat transfer properties into the flow path 6620.
  • the flow member 6610 (and any of the flow members described herein) can have a thickness of less than about 0.5 mm. In some embodiments, the flow member 6610 (and any of the flow members described herein) can have a volume about 150 microliters or greater, and the flow can be such that at least 10 microliters of sample is amplified. In other embodiments, at least 20 microliters of sample are amplified by the methods and devices described herein. In other embodiments, at least 30 microliters of sample are amplified by the methods and devices described herein. In yet other embodiments, at least 50 microliters of sample are amplified by the methods and devices described herein.
  • the heater 6630 can be any suitable heater or collection of heaters that can perform the functions described herein to amplify the prepared solution S3.
  • the heater 6630 can establish multiple temperature zones through which the prepared solution S3 flows and/or can define a desired number of amplification cycles to ensure the desired test sensitivity (e.g., at least 30 cycles, at least 34 cycles, at least 36 cycles, at least 38 cycles, or at least 40 cycles).
  • the heater 6630 (and any of the heaters described herein) can be of any suitable design.
  • the heater 6630 can be a resistance heater, a thermoelectric device (e.g. a Peltier device), or the like.
  • the heater 6630 can be one or more linear "strip heaters" arranged such that the flow path crosses the heaters at multiple different points. In other embodiments, the heater 6630 can be one or more curved heaters having a geometry that corresponds to that of the flow member 6610 to produce multiple different temperature zones in the flow path.
  • the amplification module 6600 is generally described as performing a thermal cycling operation on the prepared solution S3, in other embodiment, the amplification module 6600 can perform any suitable thermal reaction to amplify nucleic acids within the solution S3. In some embodiments, the amplification module 6600 (and any of the amplification modules described herein) can perform any suitable type of isothermal amplification process, including, for example, Loop Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA), which can be useful to detect target RNA molecules, Strand
  • LAMP Loop Mediated Isothermal Amplification
  • NASBA Nucleic Acid Sequence Based Amplification
  • SDA Displacement Amplification
  • MDA Multiple Displacement Amplification
  • RAM Ramification Amplification Method
  • a molecular diagnostic test device includes a reverse transcription (RT-PCR) module, which may be positioned between the lysis module and the amplification module.
  • RT-PCR reverse transcription
  • Reverse transcription is the process of converting RNA into cDNA.
  • RNA into cDNA One of the main reasons to do this conversion is that the subsequent cDNA can be amplified in PCR.
  • the best way to convert RNA into cDNA is by using an enzyme called Reverse Transcriptase. This enzyme, however is most efficient by itself before a PCR reaction, due to its temperature and buffering needs. However, there are instances where the RT-PCR and PCR reactions are conducted in the same tube. This requires a mix of both Reverse Transcriptase and DNA Polymerase.
  • a sample containing RNA, or suspected of containing RNA is delivered from the sample prep subsystem into a chamber that contains a dried or lyophilized pellet.
  • This pellet contains dried or lyophilized Reverse Transcriptase enzyme, dried or lyophilized reverse transcriptase reagents, and possibly the salts needed to create the correct buffering environment for the RT-PCR.
  • the pellet dissolves in the solution containing RNA and is held at a constant temperature (somewhere between 20°C and 50°C) for some period of time (from 0.1 seconds to 24 hours). During this incubation cDNA is produced from the RNA in the eluted sample.
  • the subsequent cDNA solution can then be heated at an elevated temperature (50°C to 100°C) for some time period (from 0.1 seconds to 24 hours) to inactivate the RT-PCR enzyme. After mixing the solution is now ready for PCR.
  • the device will flow the ready cDNA solution into a mixing chamber containing reagents for PCR, followed by subsequent PCR and detection as described elsewhere in this application.
  • RNA is delivered from the sample prep subsystem straight into a mixing chamber that contains dried or lyophilized reagents for one-step RT-PCR.
  • This one- step RT-PCR reaction may be done either because a special enzyme is used that can do both the RT-PCR and conventional PCR tasks, or it is done by a mixture of both RT and DNA polymerase. After mixing (and possibly incubating at 30-60°C for 0.1 second to 1 hour) the solution is now ready for PCR. The reaction is processed through subsequent PCR and detection.
  • RNA elution volume may enter port 1901 and flow into chamber 1902 designed to hold approximately 300 ul of fluid.
  • Chamber 1902 holds a lyophilized pellet consisting of suitable RT-PCR reagents.
  • Heater 1904 heats the bottom of the assembly, both the holding chamber (1903) and the serpentine channel (1905).
  • the chamber is elevated to a temperature T RT , between 20 C and 50 C, which is optimal for the RT reaction.
  • the entering fluid hydrates the lyophilized pellet.
  • the liquid in chamber (1903) is incubated for time t 1 (0.1 to 24 hours) and then the chamber and serpentine flow channel is elevated to Tinac t , (85-95 C) a temperature suitable for inactivation of inhibiting reagents.
  • a flow is caused by a vacuum or positive pressure to move the fluid from the holding chamber (1902, 1903) through a serpentine channel (1905) to a port 1906 where fluid exits to the next step.
  • the serpentine channel is designed to have a cross-section with an aspect ratio (channel height to width) to maximize the area in contact with heater allowing efficient heat coupling to the fluid.
  • the flow rates in the channel are set to achieve a minimum dwell time in the channel to achieve reagent inactivation.
  • the RT module may be identical to an inactivation module described herein. In some embodiments, the RT module may be identical to an inactivation module described herein, expect for the presence of lyophilized RT enzyme and other components required for the RT reaction. In some embodiments the RT module may resemble any one or more of the inactivation modules shown in FIGs: 13-24.
  • the RT module and the inactivation module may be the same module.
  • the inactivation and RT module may comprise two output ports, a first output port which leads into a chamber which contains a lyophilized RT enzyme and then connects back to the input port of the module, and a second output port which leads to the mixing chamber.
  • the first output port may connect back to the input port via a one way valve.
  • the devices described herein may include and/or be coupled to an amplification module or PCR module of the types shown and described herein, in which a polymerase chain reaction may be performed.
  • the amplification module may be proceeded by a mixing chamber in which the nucleic acid is mixed with components for performing a polymerase chain reaction.
  • components which may be required for a polymerase chain reaction include nucleotide triphosphates, polymerase enzymes, nucleic acid primers, calcium ions and buffer.
  • all components of the reaction mixture may be present in the sample buffer.
  • the sample buffer may comprise all components except for a polymerase enzyme which may be provided in the mixing chamber.
  • the choice of polymerase enzyme may depend on the purification and lysis protocol used.
  • the devices may also comprise a detection module which is capable of detecting nucleic acids amplified in the amplification module.
  • the devices described herein may be contained with a housing.
  • the device is self-contained.
  • the device is a handheld device.
  • the device is configured for one-time use (e.g., disposable).
  • the devices may generate a nucleic acid sample that may be collected prior to performing one or more downstream
  • the sample can be held in a chamber or reservoir within the housing of the device or can be relayed to a chamber or reservoir that sits outside of the housing of the device.
  • the device is coupled to one or more additional devices that can perform the one or more downstream applications, for example, a device that can perform a polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • Example 1 Comparison of a traditional DNA extraction method versus an embodiment of the methods described herein.
  • DNA was extracted from clinical samples using either a standard DNA extraction protocol or a DNA extraction protocol using the methods described herein.
  • Clinical samples that were positive for Neisseria gonorrhoeae and/or Chlamydia trachomatis (Samples 101, 105, 108, 117 and 122) were obtained and screened for the presence of these bacteria ⁇ See Table 1).
  • These samples were processed utilizing two different methods for DNA extraction. For the first method, 500 ⁇ of each of these samples were taken for DNA extraction utilizing the Qiagen QIAmp® DNA Mini Kit according to the manufacturer's recommendations for isolation of bacterial DNA from bodily fluids ("standard method").
  • 500 ⁇ of each of the samples were taken for DNA extraction utilizing an embodiment of the methods provided herein. Briefly, 500 ⁇ of the sample was preloaded into a clean syringe and lmL of air was aspirated into the same syringe. The syringe containing both the sample and air was connected to the filter housing and the entire volume was pushed through (i.e., liquid followed by air). A new syringe was preloaded with 600 ⁇ of wash solution, then the wash solution was pushed through the filter housing. The orientation of the filter was flipped and a female luer lug was attached to the end.
  • TT buffer Tris Acid, Tris Base, Tween 80, Antifoam SE-15, ProClinTM300 and molecular grade water
  • TT buffer Tris Acid, Tris Base, Tween 80, Antifoam SE-15, ProClinTM300 and molecular grade water
  • the 1.5 mL tube was preloaded with a lyophilized proteinase K pellet.
  • the tube was incubated in a heat block at 56°C for 1 minute to allow for optimal proteinase K activity.
  • the proteinase K was heat inactivated by placing the tube in a heat block at 95°C for 10 minutes.
  • Each sample was mixed with PCR reagents. Primer/probe sets designed to amplify sequences from several different organisms were added to each sample. 1 ⁇ . of N. subflava DNA (1,000 copies/rxn) were added to the sample/PCR mix designated for the NS assay. The mixtures were divided into two wells of 20 ⁇ . each on a LightCycler® plate. The plate was loaded onto the LightCycler® Real-Time PCR System (Roche) and run under the following PCR conditions: Stage 1 : 95C for 20 seconds
  • Stage 2 40 cycles of: 95 C for 1 second, 60C for 6 seconds
  • FIGS. 3 and 4 depict a comparison of data generated from real-time PCR reactions performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 117) utilizing the methods provided herein versus standard DNA extraction methods.
  • Primer Set #1 detected the presence of N. gonorrhoeae in Sample 122 prepared using either method as shown in FIG. 3.
  • Primer Set #2 detected the presence of N. gonorrhoeae in both Sample 122 and Sample 117, prepared using either method as shown in FIG. 4.
  • FIGS. 5 and 6 depict a comparison of data generated from real-time PCR reactions performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122), and clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods. Both standard (“Qiagen”) and new methods (“Click”) of DNA extraction did not detect the presence of C.
  • Primer Set #3 was able to detect the presence of C. trachomatis in Samples 108, 122 and 101 using either sample preparation method (FIG. 5).
  • Primer Set #4 was able to detect the presence of C. trachomatis in Sample 101 for both sample preparation methods, and only Sample 122 for the standard method, and only Sample 108 for the new method (FIG. 6).
  • FIGS. 7 and 8 depict a comparison of data generated from real-time PCR reactions performed on N. gonorrhoeae positive control DNA or C. trachomatis positive control DNA, respectively, utilizing different sets of primers.
  • FIG. 9 depicts data generated from a real-time PCR reaction performed on N.
  • Example 2 PCR amplification from samples purified without a filter step
  • DNA was purified from a range of samples using the no filter method described herein. Briefly samples are flowed into the holding chamber of the inactivation module, the heat-treated fluid is flowed through the serpentine path and into a mixing chamber containing PCR reagents. PCR is performed and PCR products are detected. In this example, purified DNA is subjected to PCR using the probe sets of example 1.
  • FIG. 25 shows successful PCR amplification from DNA isolated from 19 different clinical samples, shown in Table 2, using this method.
  • FIG. 26 shows the results of PCR amplification on DNA extracted from the samples in Table 3.
  • Samples in Table 2 were purified in buffer comprising 50 mM Tris pH 8.4, Tween-80, 2% (w/v), BSA, 0.25% (w/v), Proclin 300 0.03% (w/v), and Antifoam SE-15, 0.002% (v/v) made up in purified water, (TT buffer).
  • Amplification was seen in every sample indicating that the PCR reaction possesses high tolerance to inhibitors.
  • FIG. 27 depicts the result of an experiment comparing different sample buffers.
  • the sample buffers used were the TT buffer described above, MSwab buffer (MS; Copan Diagnostics, CA), and Liquid Amies Buffer (LA; Copan Diagnostics, CA).
  • PCR products were run on 4% agarose gels to determine the success of the PCR reaction. Samples rehydrated in TT buffer amplified as expected, equal to the controls. The other two medias MS and LA showed varying results, suggesting variable inhibition of the PCR by contaminants from the sample buffer.
  • Affinity nanoparticles were prepared with seven different affinity baits.
  • the affinity nanoparticles were incubated with viral supematants containing Rift Valley fever virus (RVFV, 1E+7 pfu/ml) for 30 minutes at room temperature and washed 4 times with water.
  • Viral RNA was extracted from the particles with Ambion's MagMax Viral RNA extraction kit and quantitated by qRT-PCR assays. All seven affinity baits pulled down viral nucleic acid as shown by the results in FIG. 36. To determine whether the particles were pulling down intact viral particles rather than naked nucleic acid from lysed viral particles a plaque forming assay was conducted.
  • Viral supematants were incubated with NT46, NT53, and NT69 for 30 minutes at room temperature and washed 4 times with water. Captured viruses were not eluted off of the NanoTrap particles, but rather the samples were diluted and added directly to Vero cells (a kidney epithelial cell line) during the plaque assay procedure. All three affinity nanoparticles tested were capable of pulling down intact infectious viral particles and causing plaques as compared to a control sample without viral particles (-RVFV), as shown in FIG. 37. Further details about viral pull down with affinity particles, such as those in this example, may be found in Shafagati N, et al. (2013) The Use of NanoTrap Particles as a Sample Enrichment Method to Enhance the Detection of Rift Valley Fever Virus. PLOS Neglected Tropical Diseases 7(7): e2296.
  • any of the devices and methods described herein are not limited to performing a molecular diagnostic test on human samples.
  • any of the devices and methods described herein can be used with veterinary samples, food samples, and/or environmental samples.
  • the fluid transfer assemblies are shown and described herein as including a piston pump (or syringe), in other embodiments, any suitable pump can be used.
  • any of the fluid transfer assemblies described herein can include any suitable positive-displacement fluid transfer device, such as a gear pump, a vane pump, and/or the like.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Clinical Laboratory Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Fluid Mechanics (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plasma & Fusion (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes et des dispositifs pour préparer un échantillon de molécules d'acides nucléiques à partir d'un échantillon biologique. L'efficacité de ces méthodes et ces dispositifs peut être similaire ou supérieure à celle des méthodes de préparation d'échantillons standard. Les molécules d'acides nucléiques préparées en faisant appel aux méthodes et dispositifs selon l'invention peuvent être utilisées pour des applications en aval, notamment pour la réaction en chaîne par polymérase (PCR)
EP17821297.3A 2016-06-30 2017-06-29 Dispositifs et méthodes d'extraction d'acides nucléiques Withdrawn EP3478417A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357306P 2016-06-30 2016-06-30
PCT/US2017/040112 WO2018005870A1 (fr) 2016-06-30 2017-06-29 Dispositifs et méthodes d'extraction d'acides nucléiques

Publications (2)

Publication Number Publication Date
EP3478417A1 true EP3478417A1 (fr) 2019-05-08
EP3478417A4 EP3478417A4 (fr) 2020-01-15

Family

ID=60785483

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17821297.3A Withdrawn EP3478417A4 (fr) 2016-06-30 2017-06-29 Dispositifs et méthodes d'extraction d'acides nucléiques

Country Status (6)

Country Link
US (1) US20200086324A1 (fr)
EP (1) EP3478417A4 (fr)
CN (1) CN109661273B (fr)
AU (2) AU2017290753B2 (fr)
CA (1) CA3029682A1 (fr)
WO (1) WO2018005870A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195610B2 (en) 2014-03-10 2019-02-05 Click Diagnostics, Inc. Cartridge-based thermocycler
EP4029606A1 (fr) 2014-12-31 2022-07-20 Visby Medical, Inc. Test diagnostique moléculaire
WO2017185067A1 (fr) 2016-04-22 2017-10-26 Click Diagnostics, Inc. Dispositif de chauffage de carte à circuit imprimé pour un module d'amplification
WO2017197040A1 (fr) 2016-05-11 2017-11-16 Click Diagnostics, Inc. Compositions et méthodes d'extraction d'acides nucléiques
MX2018015889A (es) 2016-06-29 2019-05-27 Click Diagnostics Inc Dispositivos y metodos para la deteccion de moleculas usando una celda de flujo.
CA3078976A1 (fr) 2017-11-09 2019-05-16 Visby Medical, Inc. Dispositif de diagnostic moleculaire portatif et procedes de detection de virus cibles
CN113438925B (zh) * 2018-12-13 2024-03-29 戴格诺斯厄利公司 用于收集挥发性有机化合物的装置、方法和系统
CN110862907B (zh) * 2019-12-06 2021-10-08 中国科学院长春光学精密机械与物理研究所 一种核酸提取预处理扩增系统
WO2021138544A1 (fr) 2020-01-03 2021-07-08 Visby Medical, Inc. Dispositifs et procédés d'essai de susceptibilité aux antibiotiques
US20230149928A1 (en) * 2020-04-03 2023-05-18 Femtodx, Inc. Sensor-based systems and methods for diagnostic and field use detection of nucleic acids
WO2021243308A2 (fr) * 2020-05-29 2021-12-02 Mammoth Biosciences, Inc. Dispositif de diagnostic à nucléase programmable
WO2022085007A1 (fr) * 2020-10-23 2022-04-28 Technion Research & Development Foundation Ltd. Dispositif, systèmes et procédés de détection de molécules d'acide nucléique d'intérêt
GB2611355A (en) * 2021-10-04 2023-04-05 52 North Health Ltd Assay device for a suspension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232829A (en) * 1989-09-29 1993-08-03 Hoffmann-La Roche Inc. Detection of chlamydia trachomatis by polymerase chain reaction using biotin labelled lina primers and capture probes
US5254479A (en) * 1991-12-19 1993-10-19 Eastman Kodak Company Methods for preventing air injection into a detection chamber supplied with injected liquid
AU677781B2 (en) * 1992-05-01 1997-05-08 Trustees Of The University Of Pennsylvania, The Microfabricated sperm handling devices
ATE409238T1 (de) * 2000-05-12 2008-10-15 Caliper Life Sciences Inc Nachweis der hybridisierung von nukleinsäuren durch fluoreszenzpolarisation
WO2007061943A2 (fr) * 2005-11-21 2007-05-31 Applera Corporation Appareil portatif de preparation, d'analyse et de detection pour le traitement d'acides nucleiques
GB0617035D0 (en) * 2006-08-30 2006-10-11 Inverness Medical Switzerland Fluidic indicator device
KR101228308B1 (ko) * 2007-05-23 2013-01-31 삼성전자주식회사 미세유동 칩을 이용한 디스크형 미세유동장치 및 생체물질마이크로어레이 칩을 이용한 디스크형 미세유동장치
US20090186344A1 (en) * 2008-01-23 2009-07-23 Caliper Life Sciences, Inc. Devices and methods for detecting and quantitating nucleic acids using size separation of amplicons
US20110312541A1 (en) * 2010-06-17 2011-12-22 Geneasys Pty Ltd Loc for detection of hybridization of nucleic acid sequences with primer-linked linear probes
US10519492B2 (en) * 2011-04-20 2019-12-31 Mesa Biotech, Inc. Integrated device for nucleic acid detection and identification
CN104023834B (zh) * 2011-05-04 2016-09-28 卢米耐克斯公司 用于集成的样品制备、反应和检测的设备与方法
US9435765B2 (en) * 2011-07-22 2016-09-06 Tecan Trading Ag Cartridge and system for manipulating samples in liquid droplets
MX370922B (es) * 2012-05-11 2020-01-09 Temptime Corp Indicador de calor de función dual y método de fabricación.
CA2877368C (fr) * 2012-06-29 2021-07-13 General Electric Company Kit pour l'amplification d'adn isotherme a partir d'une matrice d'arn
EP4029606A1 (fr) * 2014-12-31 2022-07-20 Visby Medical, Inc. Test diagnostique moléculaire

Also Published As

Publication number Publication date
EP3478417A4 (fr) 2020-01-15
CA3029682A1 (fr) 2018-01-04
AU2022201584A1 (en) 2022-03-31
AU2017290753B2 (en) 2021-12-09
CN109661273B (zh) 2022-11-04
CN109661273A (zh) 2019-04-19
WO2018005870A1 (fr) 2018-01-04
AU2017290753A1 (en) 2019-01-24
US20200086324A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
AU2017290753B2 (en) Devices and methods for nucleic acid extraction
US11193119B2 (en) Devices and methods for nucleic acid extraction
US20200406257A1 (en) Devices and methods for the detection of molecules using a flow cell
US12037635B2 (en) Portable molecular diagnostic device and methods for the detection of target viruses
US10987674B2 (en) Printed circuit board heater for an amplification module
JP6026570B2 (ja) 高度に単純化された側方流動ベースの核酸サンプル調製および受動的流体流動制御
CN109851711B (zh) 可溶性水凝胶微球及其制备方法与在单细胞检测中的应用
JP6437917B2 (ja) 試料調製方法及びシステム
US10196632B2 (en) Nucleic acid extraction using organic solvents to remove inhibitors
CN108410951A (zh) 一种新的核酸提取试剂及其应用
Saleh et al. Rapid detection of Cyprinid herpesvirus-3 (CyHV-3) using a gold nanoparticle-based hybridization assay
KR102239349B1 (ko) 벌크 액체들 내의 물질들을 시퀘스터링하기 위한 시스템들 및 방법
CN107287337A (zh) 使用定量pcr和数字pcr进行核酸检测的新颖制剂、方法和系统
US20240218466A1 (en) Devices and methods for detection of target viruses
Kang et al. A membrane-based electro-separation method (MBES) for sample clean-up and norovirus concentration
DE102010043015B4 (de) Verfahren zur Konzentration von Probenbestandteilen und Amplifikation von Nukleinsäuren
TWI645040B (zh) 登革熱病毒及屈公病毒的濃縮及純化方法
WO2022082016A1 (fr) Lignes de régulation de débit pour dosages à écoulement latéral
Geng Microfluidics for genetic and epigenetic analysis of cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191217

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 21/29 20060101ALI20191211BHEP

Ipc: G01N 30/88 20060101ALI20191211BHEP

Ipc: C12Q 1/68 20180101ALI20191211BHEP

Ipc: B01L 3/00 20060101AFI20191211BHEP

Ipc: C12N 9/12 20060101ALI20191211BHEP

Ipc: B01L 7/00 20060101ALI20191211BHEP

Ipc: C12N 15/10 20060101ALI20191211BHEP

Ipc: G01N 21/78 20060101ALI20191211BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VISBY MEDICAL, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240522